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The ketogenic diet (KD) is an effective mode of therapy for epilepsy, although the 
mechanism(s) of action remains unknown. In investigating mechanism(s) of 
action, controlling for dietary factors, such as protein, fiber, vitamins and 
minerals, is a critical component of experimental design, particularly as many 
nutrients modify metabolism and gene regulation. Furthermore, experimental 
nutrient and energy deficient diets are not readily applicable to humans. 
Nonetheless, a nutritionally adequate nutrient-controlled KD has not previously 
been developed and evaluated for utility in an experimental model. In this study, 
we tested the efficacy of novel ketogenic and calorie restricted diets while 
maintaining consistent protein, fiber and micronutrient levels across groups in a 
natural model of epilepsy. Female EL/Suz mice(n=20), 100-200 days old, were 
randomized into four groups to independently assess the effects of carbohydrate 
and fat modification as well as calorie restriction. Groups included control (C), 
calorie-restricted (CR), ketogenic (KD), and ketogenic calorie-restricted (KDCR) 
diets. Mice were on treatment for 4.5-5.5 weeks.  Energy levels for the calorie-
restricted groups were reduced to 75% of control levels. The ketogenic groups 
(KD and KDCR) experienced a trend toward seizure control over the non-
ketogenic groups (C and CR) although the differences were not significant.  Body 
weights decreased significantly in the CR and KDCR groups while plasma 
glucose levels did not differ among groups and plasma beta-hydroxybutyrate 
(BHB) levels increased in the KD and KDCR groups. Mouse body weight at week 
4, as well as the change in body weight at week 4 from baseline, was 
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significantly related to seizure control.  Mice that had stable weight or weight loss 
were more likely to experience seizure control than mice that gained weight.  The 
results from this study suggest that ketosis indicated by elevated BHB levels and 
energy restriction indicated by weight loss correspond to lower seizure 
susceptibility in an experimental model of naturally occurring epilepsy. Nutrient-
controlled experimental diets can and should be used for investigating KD 
mechanisms in experimental models. 
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Research hypothesis and specific aims  
 
 
Although the ketogenic diet was medically recognized in the 1920s as a viable 
treatment for intractable pediatric epilepsy, the underlying mechanism(s) is 
unknown.  While more and more researchers have undertaken the task to 
explore mechanisms underlying the efficacy of the ketogenic diet, experimental 
diet designs in animal models have generally been poorly controlled and/or 
deficient in essential nutrients. 
 
The central hypothesis is that ketosis elicited through highly controlled 
experimental ketogenic diets and calorie restricted diets with equivalent protein, 
fiber, and micronutrient intake across groups will decrease seizures in a natural 
mouse model of epilepsy.  The proposed research will examine seizure control 
and metabolic parameters exerted by ketogenic diets and calorie- restricted diets 
in which protein, fiber and micronutrients are standardized. 
 
The rationale for this study is that typical experimental designs that have been 
used in studying this diet have not included control measures for nutrient intake 
across groups, thus yielding results that cannot be readily interpreted.   By 
controlling for protein, fiber and micronutrients in experimental designs, study 
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results can be more clearly interpreted, thus enhancing the overall knowledge of 
mechanisms involved in seizure control. Insights into the mechanism(s) of this 
proven treatment could improve the implementation of the treatment and 
therefore maximize the utility of the ketogenic diet in children and adults with 
intractable epilepsy. 
 
To test the central hypothesis, the following specific aims are proposed: 
1.  Determine the extent to which a nutrient controlled ketogenic 
diet exerts anti-epileptic effects in a natural mouse model of 
epilepsy.  Working hypothesis:  A high fat, low carbohydrate 
ketogenic diet reduces epileptic seizures in a natural model of 
epilepsy when intake of protein, fiber, and micronutrients are 
maintained at consistent levels. 
 
2.  Determine the extent to which a nutrient controlled calorie-
restricted diet exerts anti-epileptic effects in a natural mouse 
model of epilepsy.  Working hypothesis:  A calorie-restricted diet 
reduces epileptic seizures in a natural model of epilepsy when intake 














Epilepsy is a debilitating neurological disorder affecting more than 3 million 
Americans, many of them children (1).  In the US alone, 200,000 people will 
receive a diagnosis of epilepsy this year (1).  A majority of epilepsies are of 
idiopathic origin, meaning there is no known precipitating event or known defect 
attributed to the cause of the disorder (1, 2).     
 
 Epilepsy is characterized by the tendency to experience periods of sudden 
deviations in the way a person feels or acts due to an excessive electrical 
discharging of neurons in either a section or the entire brain.  These periods of 
electrical discharge can range in duration from a mere few seconds to extended 
seizure activity such as with status epilepticus in which can only be stopped with 
heavy sedation such as inducing a coma in the patient.  Epilepsy can include 
seizures of several types, including generalized seizures that involve the entire 
brain.  Examples of these generalized events include tonic-clonic (formerly grand 
mal) seizures and absence seizures (formerly petit mal).  Other seizure types 
include partial seizures that do not affect the entire brain but only part.  The area 
of the brain affected will determine how the seizure presents (what the seizure 
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will look like or feel like).  For example, a seizure in the motor cortex of the frontal 
lobe may result in involuntary movements of a hand or leg.  Partial seizures can 
be further classified as partial simple or partial complex.  The patient affected by 
a partial simple seizure typically remains aware of the event and can recall what 
took place during the event (consciousness is maintained).  This seizure type is 
isolated to one of any sections or lobes of the brain.  The complex seizure begins 
in the temporal or frontal lobe and affects the area of the brain that regulates 
awareness and alertness, thus the patient is unaware of what is happening 
during the seizure.  The patient may have a blank stare and make meaningless 
movements such as climbing, drooling or lip smacking.  Often, after a complex 
seizure, the patient is confused and tired.  Partial seizures can remain in one 
area of the brain and resolve without affecting the remaining areas in the brain, 
or the electrical discharging could spread throughout the entire brain, thus 
evolving into a generalized seizure.   
 
Ancient writings reveal that epilepsy is not a new disorder, most likely dating 
back to the beginning of the human race.  The earliest writings available refer to 
epilepsy as the Sacred Disease due to the misconceptions that epilepsy was a 
spiritual disorder rather than physiological (3).  Varying areas of thought have 
existed and evolved in an attempt to explain epileptic events, yet much remains 
unknown about this disorder.  Throughout history, attempts to explain the 
disease have been made.  One ongoing argument has been whether the origin of 




The earliest documentation of epilepsy is found on an ancient Babylonian 
cuneiform text in the Sakikku, translated as All Diseases.  These writings were 
contained on 2 tablets that date between 1067 and 1046 BC (4).  The writings in 
the Sakikku refer to epilepsy as the falling disease and the descriptions of the 
events are laced with inferences that the person with epilepsy is possessed by 
demonic spirits (4).    One translation from an entry in these early medical 
writings reads  
If epilepsy falls once upon a person [or falls many] times, [it is (as 
the result of) possession] by a demon or a departed spirit(4).  
 Characteristics of an epileptic event such as temporary loss of consciousness, 
physical stiffening movements, rolling of eyes, foaming mouth and others oddities 
that are sometimes a part of an epileptic seizure likely contributed to this view.  
The aura that some patients experience before an event was considered the 
entering of the demon with the climax or convulsive part of the event construed 
as the time in which the demon took full possession.  The clonic stage, or the 
slowing, rhythmic twitching stage, was considered the letting go of the demon 
or releasing of the victim, thus ending the event (4).    This ancient writing also 
includes attempts to diagnose different seizure types (i.e., attribute to a certain 
demon) such as: 
 If the possessing demon.., and at the time of his fit he 
clenches his hands as (tightly as) though rigor (or, rigor mortis?) 
had seized him, and, with legs extended, is greatly convulsed; if 
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then the seizure abates and he begins to regain consciousness, - 
hand of the eelu-demon (4).   
In this era, nocturnal seizures were considered to be at the hand of ghosts with 
one account in the Sakikku translated:  
If his seizure (or, possession) always takes place in the evening, 
it is the seizure of a ghost (nocturnal epilepsy) (4). 
Even with the advancement of medical science, still today the notion that 
epilepsy is propagated by evil spirits remains (5, 6). Several religions today 
continue to view epilepsy a spiritual disorder and, among these religions, ideas 
are diverse as to who or what is causing the anomaly.  Hirsham Ismail and his 
team at Bradford Teaching Hospitals in the UK report that South Asian Muslims 
in the UK and the Indian subcontinent, contribute the seizures to spirit 
possession while Sikhs and Hindus attribute the events to sins committed in a 
former life (7).  A study of teachers in urban and rural Zambia reported that 28% 
of teachers considered epilepsy contagious, 17.3% attributed epilepsy to spirit 
possession, 16.8% to witchcraft (6).  This study found that these teachers were 
more likely to refer their students with epilepsy to a traditional healer as opposed 
to a physician (6). 
 
Although mystery and unknowns still surround this particular disorder, modern 
science advancements have contributed to understanding epilepsy as 
physiologic in nature, thus making it better known as a medical condition as 
opposed to a spiritual anomaly.  As early as approximately 400 BC, some were 
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questioning the spirituality of this disorder.  Of the Hippocratic writings dating 
back to 400 BC and translated in 1854, the essay that addressed this disease 
specifically appears to introduce the thought that this disease may not involve a 
spiritual element, but be a physiologic disorder.  Yet, to identify epilepsy as his 
subject, the writer(s) began with On the Sacred Disease and continued with a 
commonly quoted excerpt: 
It is thus with regard to the disease called Sacred:  it appears to me to be 
nowise more divine nor more sacred than other diseases.  But has a natural 
cause from which it originates like other affections.  Men regard its nature and 
cause as divine from ignorance and wonder, because it is not at all like to other 
diseases.  And this notion of its divinity is kept up by their inability to comprehend 
it, and the simplicity of the mode by which it is cured, for men are freed from it by 
purifications and incantations (3). 
John Hughlings Jacksons work in the mid-nineteenth century made the biggest 
impact to bring about the current view of epilepsy being physiological in nature 
(8).  Jackson believed epilepsy to be electrical in nature and originating in the 
gray matter of the brain (8).  He included pathological as well as clinical 
observation in his studies and even went on to work with a young surgeon, 
Horsley, to perform the first brain resection for epilepsy on May 25, 1886 (8).  
Jacksons vast understanding and subsequent reporting of epilepsy has opened 




With the general consensus that epilepsy is physiological in nature as opposed to 
spiritual, progress has been made toward the treatment.  Yet even with todays 
knowledge through years of clinical and basic science research, much remains 
unknown when it comes to narrowing down etiologies of epilepsy in patients.  In 




Epilepsy is a common disorder among Americans, with over 3 million diagnosed 
with the disorder.  The Epilepsy Foundation of America reports that one out of 
every 10 adults will experience a seizure in their lifetime (1).  They further predict 
that 300,000 Americans will experience their first convulsion this year, and 
120,000 of them will be children.  For a staggering 70% of them, the cause of the 
seizure will remain unknown, thus no precipitating event provoked the seizure 
(1).  Although epilepsy cannot be predicted in an individual, some populations 
are at higher risk.  Ten percent of children with mental retardation (MR) and 10% 
of children with cerebral palsy (CP) will develop epilepsy.  Fifty percent of 
children effected by both MR and CP will develop epilepsy (1).   
 
Children are not the only population at risk for epilepsy.  With the baby boomers 
expected to greatly expand the elderly population, the percentage of Americans 
affected by epilepsy could expand with it.  Three percent of those reaching 75 
years will have the diagnosis of epilepsy, with 10% having experienced at least 
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one seizure in their lifetime (1).    Other factors such as history of stroke, 
Alzheimers disease, and familial epilepsy can place an individual at greater risk 
for developing epilepsy.  Of those diagnosed with epilepsy, 30-40% will not 
respond to medications and therefore be considered intractable (9-12). 
 
Etiology/Physiology 
Seizures result when neurons conduct electrical impulses in a disordered way 
(13) .  Normal neuronal function involves the systematic firing of electrical 
impulses along the axons from one nerve cell to the next.  Neurotransmitters are 
chemicals that act as messengers to transfer information across the synaptic gap 
to the next nerve cell.  These neurotransmitters are released across the synaptic 
gap and taken up by the dendrite of the next nerve cell (13).  When the amount 
of excitatory neurotransmitters outnumbers the inhibitory neurotransmitters, the 
cell will fire; thus the signal being transferred down the nervous system 
continues.  During a seizure, these impulses do not follow the typical, systematic 
process.  A sudden neuronal misfiring radiates through the nervous system 
originating in all or part of the brain (13).  If enough neurons are involved in this 
sudden burst of neuronal misfiring, the result could be a seizure.  The misguided 
signal transfers through the nervous system and will present in many ways, 
depending on the area of the brain where the misfiring occurred.  If only a section 
of the brain is involved, the seizure could appear as modest or violent jerking, 
falling, confusion, staring or have other manifestations.   If the entire brain is 
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involved in the electrical misfiring, the result could be a convulsive seizure, 
affecting many functions of the brain (13). 
 
Epilepsy has a broad spectrum of etiologies that include physical damage to the 
brain, genetic defects, metabolic diseases and idiopathic cases in which the case 
is unknown.  Physical damage to the brain that could lead to epilepsy includes 
head trauma, a cerebrovascular accident, aneurysm, or any other condition that 
causes an injury or necrosis to the brain.  This change of structure to the brain 
can interrupt electrical homeostasis, thus putting the brain at risk of misfiring of 
the neurons (13).  The field of genetics is a growing one, as the understanding of 
the human genome is advancing.  Gene deletions and mutations that affect the 
excitability of neurons and contribute to epilepsy are being found which as lead to 
our general understanding of many idiopathic cases (14).  Metabolic diseases 
such as urea cycle disorders can cause brain dysfunction that may result in 
seizures.  Some of the presumed causes include energy failure, increased free 
radicals and possible altered neurotransmitter metabolism (15).  Other cases of 
epilepsy are idiopathic in nature, meaning the cause is unknown.  Neurons 





Epilepsy that does not respond to treatment is considered intractable epilepsy.  
Thirty to 45% of patients with epilepsy will fall into this intractable category (9-12). 
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This lack of seizure control goes beyond just a physical impairment, as social 
acceptance and self-esteem issues could result.  Psychiatric comorbidities are 
common with epilepsy and may include increased anxiety, psychotic disorders, 
and depression (16).    Individuals with epilepsy face a social stigma that can 
impact quality of life in many ways and this could be magnified if the person is 
consistently experiencing uncontrolled seizures.  People with epilepsy are often 
viewed as violent individuals during and in between seizure events (17).  The 
patient with epilepsy who fails to respond to medical treatment is at greater risk 
of personal injury, learning disabilities, social embarrassment, unemployment, 
inability to drive, and an overall decrease in living independently (18).  In fact, the 
social impact for people with childhood epilepsies is more profound than with any 
other chronic disease state (19) .  These individuals are less likely to live 
independently and form functional life relationships (19).   
 
The intractability of epilepsy is poorly understood, as predictability of who will or 
will not respond is limited.  Two subjects can present with virtually identical 
seizure activity and/or etiology, yet respond differently to treatment.  For 
example, Dr. Jacqueline French reported on 2 sisters with idiopathic generalized 
epilepsy that developed in each during adolescence.  One of the siblings was 
successfully treated with antiepileptic drugs (AEDs) and the other was 
intractable, thus failing multiple AEDs.  The clinical outcomes of these siblings 
were very different, despite similar presentations and genetics (12). Little is 
known as to why some would respond and others would not.  This lack of 
 
 12
understanding is problematic in treating persons with epilepsy, as outcomes 
cannot be predicted and treatment choices cannot be standardized.   
 
Failure of the first prescribed AED increases the risk of intractability.  Kwan & 
Brodie found that out of the 525 patients at their center in Glasgow, Scotland, 
that 47% of their patients became seizure free after initiation of the first AED.  
Only 13% became seizure free on the second monotherapy choice and a mere 
1% realized seizure freedom on the 3rd choice (20).  Thus, risk of intractability 
rapidly increases with the failure of each subsequent AED.  This goes along with 
the common notion that after a child has failed 2 mainline AEDs, the likelihood of 
finding a medication to control seizures is minimal (20).  Antiepileptic drugs 
continue to be prescribed after the failure of 3 AEDs and are often pushed 
beyond therapeutic levels to toxic levels in an attempt to gain some seizure 
control (21).    This is problematic especially to the developing brain of a child.  
Polypharmacy is also a concern in this population, as clinicians add medications 
to the current one(s) to offer an attempt at seizure control (21).  Not only are 
individuals taking multiple seizure medications at risk of adverse effects, they can 
sometimes realize an adverse effect of worsening seizures (22).  And with some 
epilepsies progressive in nature, the disease state could worsen due to the 
intractability of the epilepsy, despite AEDs prescribed (12).  
 
Baker, et al found that for the patient with epilepsy, the most important variable in 
determining quality of life is freedom of seizures (23); therefore, clinicians are 
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challenged to find treatment options and combination of options that control the 
seizures.  Those with intractable epilepsy pose the biggest challenge. 
 
History of Treatments 
 
As expected, the historical treatment of epilepsy is as diverse as the beliefs and 
understandings of the disorder itself.  Throughout the years, remedies have 
included exorcism and warding off spirits, dietary regimens, medications and 
surgery (11, 24-26).  Though medical advancement has produced a clearer 
picture of the nature of the disorder, all these different treatment approaches are 
used today. Even the less-than-conventional ones continue to be used in some 




 Antonius Guainerius in the early 15th century wrote of sacred medicine to treat 
this sacred disease.  The prescription included intake of a frogs liver, blood to 
smear on the patients mouth, bile from a freshly killed dog, and urine given to 
him/her from the shoe of the first person to see the seizure (27). One can only 
imagine the fear and despair surrounding the disorder that has a treatment of 
such extremes.  Yet, when etiology is presumed to be spiritual in nature, it seems 
logical to treat with spiritual tools.  Still today, some religions ascribe to epilepsy 






With emerging understanding of epilepsy came more modern treatments.  Anti-
epileptic drugs (AEDs) were first reported in use in 19th century. 
 
The bromides were the first known antiepileptic drug (AED) class to treat 
epileptic seizures.  The English physician, C.B. Radcliffe, first reported in 1860 
that Sir Charles Locock had found some success with using potassium bromide 
for a myriad of neurological disorders, of which he included epilepsy (28). 
However, these drugs were not greatly utilized in treatment of epilepsy until 
Horase Y. Evans reported his concerns about their underutilization in an article in 
the American Journal of Medical Science in (28).  Following this publication and a 
few clinical studies offering some evidence of efficacy, the bromides gained 
popularity and usage.  Yet, these clinical studies were far from the class I studies 
of today and there was little drug standardization.  Authors of an English review 
of the literature on the subject reported a minimum of 45 different preparations 
(28).  Regardless, this served as a first attempt at treating this disease 
medicinally.   
 
At the turn of the twentieth century, barbiturates were becoming more readily 
used in the field of neurology (29).  Of this class of drugs, phenobarbital was 
found to have some anti-epileptic properties around 1912 (29).    At this point, 
bromide therapy was beginning to lose its favor.  In fact, around this time the 
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former president of the National Association of the Study of Epilepsy, W. C. 
Graves, described the patient on bromides as being made to live a living death 
as descriptive of their decrease in cognitive functioning while on the drug (28).  
Phenobarbital, too, had its sedative drawbacks, nonetheless, a second option 
had been added to the choices of drugs for epilepsy.  This was the beginning of 
what could be classified as 1st generation AEDs.  These AEDs were not 
scrutinized by the class I, double blinded, randomized trials that the 2nd 
generation AEDs underwent. 
 
A major breakthrough in drug therapies for epilepsy came with the introduction of 
phenytoin in the 1937 (30).  In fact, this one AED revolutionalized epilepsy 
treatments and was the first of a flurry of new AEDs, targeting differing epilepsy 
types.  These new medications were much needed in those days, as the 2 AEDs 
previously mentioned had such sedative side effects.  Yet, AEDs developed in 
the mid 1900s had their drawbacks.  For example, side effects such as gingival 
hyperplasia and hirsutism were seen in patients prescribed phenytoin.  Digestive 
and liver function as well as behavioral side effects were seen with valproic acid 
(31, 32).  Both of these AEDs are still in use today (clinical observation), despite 
well documented side effects. 
 
The 1990s brought the introduction of the 2nd generation of AEDs.  These drugs 
were subjected to more rigorous testing that was mandated by the Food and 
Drug Administration.  Although these newer medications seemed to have fewer 
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side effects and appeared safer, efficacy rates have not improved (33).  While 
pharmaceutical treatments appear easier and are more readily used in treating 
epilepsy than alternative therapies, they are not without disadvantages.  
Clinicians are challenged to effectively treat their patients with epilepsy; therefore 
they often will prescribe AEDs to near toxic levels in an attempt to gain seizure 
control (12).  And the impact of AEDs on the maturing brain, as in neonates and 
children, is still uncertain.  Animal studies have suggested that these AEDs could 
impact development negatively (34).  While numerous AEDs are available, 
effectiveness of each varies by seizure type.  Many AEDs are accompanied by 
serious side-effects such as hepatotoxicity, anorexia, weight gain, and sleep, 




Surgical interventions, including temporal lobectomy, hemispherectomy, corpus 
callosotomy, or vagus nerve stimulation, are invasive procedures and have their 
own disadvantages.  In evaluating for candidacy of lobectomy or 
hemispherectomy surgeries, patients typically undergo a rigorous screening by a 
multidisciplinary medical team to determine if a seizure focus can be found and 
further removed without loss of function (36).  Neuroimaging, neurophysiology, 
and neuropsychology disciplines contribute to evaluate a patient to determine 
whether a seizure focal point can be found in the brain and if it can be removed 
without compromising function.  Some potential risks of these brain surgeries 
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could include decreased memory, movement, or speech functions (36).  Though 
seizure freedom results have been reported as high as 87% for some types of 
resection, long-term and developmental outcomes are still unclear, especially in 
children (36).  Corpus callosotomy surgery is a palliative treatment for intractable 
epilepsy, as the purpose is not to control seizures as with other surgeries, but to 
stop the flow of electrical discharge from generalizing (involving the entire brain) 
during the seizure (37).  It is hypothesized that the corpus callosum is the 
pathway in which electrical impulses travel from one side of the brain to the 
other; therefore surgically disconnecting part of all of the corpus callosum has 
been shown to eliminate generalized seizures in up to 80% of patients in some 
studies (37).  Yet this treatment is not without possible adverse effects, as 
language impairment, memory deficits, new seizure types, and other neurological 
effects have been reported in as many as 27% (37). Vagus nerve stimulation 
involves implantation of a pacemaker type device into the chest cavity that is 
connected via leads to the vagus nerve which is responsible for sending 
messages to the brain (38).  The device can be programmed to send periodic or 
spontaneous electrical charges to the brain (38).  One study reported 37% of 
patients had at least a 50% reduction in the first year of use (38).  This treatment 
includes surgical risks of infection as well as side effects of throat pain, 
constriction of the throat, and voice change.  In most patients these effects were 





Dietary treatments for epilepsy date back to the Hippocrates era and biblical-
times when fasting was the mainstay for this disorder (13).  Diets that mimic 
starvation have been developed and continue to be used today (13).  These diets 
are commonly referred to as ketogenic diet, as they induce ketosis in the body.  
Ketogenic diets are typically high in fat and low in carbohydrate.  The classic 
ketogenic requires a strict adherence to dietary restrictions.  This diet typically 
requires that all foods are weighed on a gram scale to comply with a strict fat to 
non-fat diet ratio (13, 39).  Macronutrient details must be available for each food 
in the diet so that meal plans can be precisely calculated to adhere to the strict 
diet ratio and kcalorie allotments. Such a restrictive diet can be difficult to comply 
with, yet for those with intractable epilepsy the tight restrictions may be merited.  
Ketogenic diets are used worldwide (38, 40) and researchers are fast at work to 
maximize this treatments potential and uncover the mechanisms that make it 
effective.  A more detailed overview of dietary treatments for epilepsy is covered 
in the next section. 
 
The Classic Ketogenic diet 
 
The ketogenic diet (KD) is an attractive alternative for the treatment of epilepsy. 
This treatment requires the patient to strictly adhere to a dietary regimen 
consisting of high fat, adequate protein, and few carbohydrates (13).  Often this 
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treatment is reserved as last resort possibly due to the dietary restrictions and 
rigidity of the treatment (13).  
 
History and Current Use 
 
Historically, starvation was a mainstay in the treatment of epilepsy as described 
in the historical review compiled by Bailey et.al., with even Hippocrates 
acknowledging its benefits (41). In the early 1900s, a fanatical magazine 
publisher of a 500,000 circulation health and physical fitness magazine brought 
light to the idea of fasting, believing that any disease state could be healed with 
enough exercise and fasting (13).   Bernarr Macfadden had gained popularity 
and influence among his readers and even hired an osteopathic physician,  
Dr. Hugh Conklin, to treat patients using fasting with many disease states such 
as diabetes, asthma, bladder disease, prostate disease, impotence, paralysis, 
liver and kidney disease, eye troubles, and epilepsy (13).  Dr. Conklin began to 
notice success, especially in the epilepsy patients, and begin to draw the 
attention of the medical community. It was not until 1921 that a practical 
application was introduced when R.M. Wilder first devised a high fat, low 
carbohydrate diet that produces ketonemia, thus mimicking starvation (42). The 
diet of the 1920s closely parallels the ketogenic diet used today for intractable 
epilepsy.  It was a primary mode of treatment for epilepsy at that time, but its use 
waned throughout the mid-20th century with the introduction of phenytoin and 
newer AEDs (see Anti-epileptic Drugs above).  KD has experienced a recent 
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resurgence of interest due to its effectiveness in children with epilepsy refractory 
to management with AEDs. In fact, in recent years, researchers are seeking 
ketogenic diet mechanisms and testing newer, less rigorous diets that produce 
ketonemia in an attempt to make a diet for epilepsy easier on families and more 




The ketogenic diets used today to treat epilepsy are typically high in fat, low in 
carbohydrate, and provide adequate protein. Ketogenic diets are typically 
insufficient in vitamins and minerals that need to be supplemented (13, 39).  
Recommendations for supplementing the ketogenic diet include a standard 
multivitamin with minerals (including trace minerals) and calcium with vitamin D 
(13, 39).  Other supplements including oral citrates, selenium, magnesium, zinc, 
phosphorus, extra vitamin D, carnitine, MCT oil and sodium may be 
supplemented when indicated (13, 39).  Although variations of the diet have 
recently been tested, the ketogenic diet of the 1920s is surprisingly similar to the 
classic ketogenic diet (KD) used today.  The typical KD macronutrient ratio is 4:1 
by weight (4g fat:1g carbohydrate + protein), which translates to a diet in which 
90% of energy is derived from fat (45). Protein is often fed at the RDA level with 
total kilocalories reduced to 75% of requirements which permits linear growth 
while restricting weight gain (45). Historically, epilepsy centers have restricted 
fluid to 90% of needs, yet many centers have discontinued fluid restriction, as it 
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has not been shown to improve efficacy (13, 39). The basic composition has 
remained essentially unchanged over the years and is based and managed 
largely on convention and empirical evidence. 
  
Efficacy of Treatment 
 
Published findings indicate the classic ketogenic diet (KD) is more effective and 
has fewer side effects than currently-available pharmaceutical treatments (25, 
46).  Results from a recent, controlled, randomized study in the UK, indicate that 
the ketogenic diet is effective in children having at least 7 seizures per week (47).   
This study was a landmark study, as it is the first published for this treatment with 
a controlled, randomized design.  Findings, summarized in figure 1, included 
38% of children on the ketogenic diet experienced a >50% decrease in seizures, 
compared to the control group with 6% (47).  Seven percent of the children in the 
ketogenic diet group had >90% improvement, compared to none in the control 
group.  Unlike anti-epileptic drugs (AEDs), the ketogenic diet is efficacious across 
many seizure types (25, 46).  Figures 2 and 3 summarize results from The Johns 
Hopkins Medical Institutes and the The Clevelend Clinic of the efficacy across 
seizure types.  Use of the KD has also been associated with improved 
developmental outcomes, including significant improvement in motor skills, 
attention, and social problems (48), which can contribute to improved quality of 




Vining, et al 1998 prospective study (49) at the 3 month mark, 25% had >90% 
decrease in seizures; 29% had 50-90% decrease; thus 54% had at least a 50% 
decrease (an effect).  At the six month mark, 29% had a >90% decrease, 24% 
had a 50-90% decrease, thus 53% had an effect.  At the 12 month mark, 22% 
had >90% decrease, 18% had a 50-90% decrease.  Forty seven percent 
remained on the diet past 12 months.  This continuation on the diet can be 
construed as an indicator of efficacy due to the restrictive nature of the diet, most 
families would not continue unless improvement was seen. 
 
Variations of Classical Ketogenic Diet 
 
One common complaint about ketogenic diet therapy is that compliance with the 
rigorous regimen is hard on children and families.  In addition, some children find 
the classic ketogenic diet unpalatable.  In recent years, new approaches have 
advanced to combat these issues and make diet therapy for epilepsy a little more 
attractive to both the patient as well as the family.  These new approaches, if 











Figure 1  Neal, et. al. (2008) (47).    
A randomized trial of ketogenic diets in children at The Institute of Child Health and Great 




Figure 2  Freeman, et. al. (1998)(25) 
Prospective study of children with intractable epilepsy treated with the ketogenic diet at 
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Figure 3  Maydell, et. al. (2001)(46) 
Retrospective study of children with medically intractable epilepsy treated by the 




Dr. Eric Kossoff and his team at Johns Hopkins Medical Institutes have been 
exploring a variation of the ketogenic diet, typically referred to as a modified 
Atkins diet (MAD).  This approach allows the patient a diet that is high in fat and 
low in carbohydrates, yet, unlike the classical ketogenic diet, does not limit 
protein or overall calories.  Preliminary data suggests this diet is well tolerated 
and effective at controlling seizures in children as well as in adults (43, 50).  The 
diet remains very restrictive in allowance of carbohydrate grams, yet overall is 
more liberal as fat and protein can be increased in the diet if desired.  Foods are 
not pre-weighed by the family and overall administration of the diet is less 


















































Low Glycemic Index Treatment 
 
Dr. Elizabeth Thiele and her team at Massachusetts General Hospital in Boston, 
MA, have developed the low glycemic index treatment, an alternative to the 
classic ketogenic diet, that liberalizes the amount of carbohydrate allowed each 
day, yet restricts certain carbohydrates based on the blood glucose effect these 
foods exert (51).   In 1981, Jenkins, et al., first introduced evidence that different 
carbohydrate sources have differing effects on blood glucose when digested and 
absorbed (44, 52).  Their preliminary findings are quite impressive, as 50% of 
their patients (n=20) realized a greater than 90% reduction in seizures (44).   
Although these and the MAD findings are preliminary and from small, 
uncontrolled studies, 96% of representatives from major centers from all over the 





One of the primary focus areas of current research involves altered substrate 
utilization in the brain during ketosis.  The brain is normally an obligate user of 
glucose as its primary energy source.  However, glucose is in short supply during 
fasting or the KD and the body switches to dietary and endogenous fats as a 
source of energy.  Fatty acids undergo beta-oxidation in the liver to yield acetyl-
CoA, which, in turn, would normally enter the TCA cycle to combine with 
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oxaloacetate to yield ATP.  However, decreased intake of carbohydrate limits 
availability of sufficient oxaloacetate; therefore, acetyl-CoA accumulates to a 
level exceeding the capacity of the TCA cycle.  Acetyl-CoA molecules then 
condense to synthesize the ketone bodies acetoacetate (AcAc), beta-
hydroxybutyrate (BHB), and acetone, resulting in ketosis.  Both BHB and AcAc 
are exported to peripheral tissues for use as an energy source to many of them, 
including the brain.  These ketones are transported across the blood-brain barrier 
via facilitated diffusion using the monocarboxylate transport system.  Thus, under 
these conditions, the brain converts from glucose oxidation to utilization of 
ketones as its primary energy source (53).  
 
Consequently, it has been proposed that ketones exert a direct anti-epileptic 
effect.  Acetone and AcAc have been shown to suppress seizures (54, 55), while 
BHB has not been shown to be effective (54, 55), Elevated plasma BHB is 
commonly monitored as a measure of ketosis and is somewhat correlated with 
degree of seizure control (56), although it may simply be a marker of ketosis, 
indicating diet compliance.  Nonetheless, it remains unknown how (and if) these 
ketones are involved in the diets anti-convulsant effects.  Alternatively, it has 
been suggested that the lack of readily available glucose is responsible for 
seizure suppression (54, 55).  Seizure susceptibility in adult epileptic EL mice 
remained high when the KD was fed ad libitum and seizure control was only 
achieved when the diet was also calorically restricted to achieve a lower level of 
blood glucose (57).  Caloric restriction has been equally effective in rats (58) and 
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this same phenomenon has also been observed in children (anecdotal evidence).  
Brain glucose uptake accelerates during seizures (59) and it is possible that the 
lesser availability of glucose translates to a lack of readily available energy to 
support neuronal membrane excitability.   
 
It is also possible that the KD alters neurotransmitter synthesis and action.  The 
brain utilizes ketones to regenerate acetyl-CoA, which then enters the TCA cycle 
to produce ATP (53).  When carbohydrate availability is limited, oxaloacetate is 
depleted and, thus, no longer available for transamination of glutamate to 
aspartate, an excitatory neurotransmitter.  As a consequence, more glutamate 
becomes available for synthesis of GABA, the primary inhibitory neurotransmitter 
(60).  Indeed, modulation of GABA is one mechanism by which AEDs exert their 
effects (35).  Therefore, it is conceivable that efficacy of the KD is elicited, in part, 
via neurotransmitter modulation. 
 
Recent research indicates that metabolic changes occur in the brain as a result 
of the KD.  Bough, et. al., found the seizure threshold lowering effect of the KD 
can take weeks to develop in rats (61), thus mirroring the common clinical trial of 
at least one month to determine response (anecdotal observation).  Since the 
effect appears somewhat delayed, developmental changes induced by gene 
expression changes could be involved. Bough and his team further used 
microarray technology to study hippocampal gene expression changes induced 
by a KD in non-epileptic rats.  Their findings included a significant up-regulation 
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of metabolic genes in the hippocampus after KD treatment (61).  Similarly, Noh 
et.al., found similar effects of the KD on gene expression in the hippocampus of 
non-epileptic rats using pooled samples (62).     
 
Alterations in gene expression due to epileptic activity have also been studied 
(63) as well as AEDs (64).  However, the effects of the KD on gene expression in 
a natural model of epilepsy have not yet been determined.  Measuring KD-
induced differentiation of specific metabolic genes in an epileptic model could 
begin to bridge the gap to clinical by confirming effect in an epileptic brain.  
Possible treatment options could be perfected or developed when more is 
understood about the metabolic processes occurring in the epileptic brain when 
treated with a KD. 
 
Animal Models of Intractable Epilepsy 
Mouse Models 
 
Finding a suitable mouse model for studying epilepsy can be challenging, as 
most models used are not epileptic mice and have seizures induced by various 
techniques or chemicals.  One commonly used technique to test seizure 
threshold is the 6 Hz test.  This technique involves placing electrodes on the 
cornea of the mouse and administering electrical shocks to measure seizure 
susceptibility (65, 66).  Current intensity values are chosen utilizing a stair-
stepping method in which intensity is set dependent on how the previously tested 
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mice responded.  Mice are euthanized following testing.  Although the ketogenic 
diet has been evaluated and shown effective using this model (66), the seizures 
are not naturally occurring as in the human disorder of epilepsy. 
 
Another commonly used technique to study seizure disorders is chemical 
induction of seizures.  Researchers have used various chemicals such as 
bicuculline, picrotoxin, kainate and gamma-butyrolactone to induce seizures (67).  
These chemicals are typically administered subcutaneously in varying doses, 
depending on the level needed to induce seizures.  Each of these chemicals 
above have been used in rats in exploring the ketogenic diet (67), yet again, 
natural seizure thresholds cannot be evaluated as the seizures are induced and 




The EL/Suz (EL) mouse model is particularly suited for studying diet 
manipulation for epilepsy due to the naturally occurring seizure activity observed 
in this model without the use of chemical agents or extreme stimuli (such as 
tossing or rapid cage shaking).  This model was first described in 1959 when 
Imaizumi, et.al., observed convulsive seizures in a hydrocephalic mice strain 
after the mice endured a sudden stimuli such as tossing.  Imaizumis group went 
on to inbreed the seizure susceptible mice to develop a mutant model of 
generalized epilepsy (68). This mouse model develops seizures in combination 
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with aging, repetitive stimuli such as handling during cage changes, and previous 
seizures (69).   
 
The use of the EL mouse is well defined in the literature and has been previously 
shown to respond well to treatment with the KD (57).  Male EL mice have been 
reported to have instances of sudden death (70) and female EL mice have been 
reported to show poor maternal care of offspring (71).  Therefore, growing and 
maintaining a colony of this model can be challenging, yet cross-breeding 
techniques can be utilized to increase colony size. 
 
Applicability to humans 
 
The EL mouse is particularly well suited for studying epilepsy as it represents 
common presentation of this disease state, secondarily generalized epilepsy 
(69).  Seizure susceptibility is inherited as an autosomal dominant trait in these 
mice and develop in response to environmental stimuli (69).  
 
With the advancement of genetic science has come understanding of some of 
the genetically linked epilepsies.  Researchers have found that gene defects of 
some of epilepsy syndromes are simple, single gene defects (72).  But these 
monogenetic epilepsies are rare.  Most human epilepsies are thought to be 
multifactorial with more than one gene involved and/or multiple contributing 
environmental factors (73).  The combination of genetic and seizure susceptible 
environmental factors are hard to duplicate in an animal model.  The EL mouse 
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combines both of these elements and therefore is well suited as an applicable 
model for the majority of generalized epilepsies.   Electrical shock and chemical 
induced seizures do not progress from physiological processes.  Therefore, the 
EL mouse model is a prime model for investigating the ketogenic diet, as its 
naturally occurring epilepsy better mimics human epilepsies. 
 
 
Dietary Design in Ketogenic Diet Research 
Experimental Diets 
 
There is little question that the KD works, but maximizing its clinical utility 
requires an evidence-based understanding of how it works.  An essential part of 
testing this treatment in the animal laboratory is designing experiments that are 
highly controlled so that findings can be accurately interpreted.  Previously, 
researchers have used ketogenic diets provided by Zeigler Bros., Inc. (Gardners, 
PA) and from Bio-Serv, F3666 diet (Bio-Serv, Frenchtown, NJ )(66, 74, 75). 
The Zeigler ketogenic diet was used by Mantis, et al., in a previous study to 
evaluate efficacy of ketogenic and calorie-restricted diets, using the EL mouse 
model.  The diet used in this study consisted of 100g fat, 0g carbohydrate, 128g 
protein, and 109g fiber per kilogram along with a standard diet for the control 
group (57).  When feeding the calorie-restricted diets, Mantis, et. al., simply gave 
less of the standard and high fat diet to the mice.  Therefore, not only did the 
mice receive less kcalories, they received less protein, fiber, vitamins, minerals 
and other ingredients.  Therefore, when seizures were decreased in the calorie-
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restricted groups, they concluded that kcalorie restriction induced this reduction 
in seizures (57).  Yet, with so many nutrients decreased in the diets the mice 
received, it is unclear exactly which nutrient deficiency could have a causative 
role in the seizure reduction.  Thus, this lack of tight control in study diet design 
could have led to unclear findings. 
 
Similar methods were reported in studies using the F3666 diet (Bio-Serv, 
Frenchtown, NJ )(66, 74, 75).   The diet is commonly reported to a 6.3:1 fat to 
non-fat ratio, yet the data sheet provided by Bio-Serv calculates to be 8.66:1 fat 
to non-fat ratio.  In studies reviewed utilizing this diet formula, again, calorie-
reduction is achieved by simply reducing the amount of chow given; therefore 
reducing the previously mentioned nutrient.  Further, extreme diet fat to non-fat 
ratios are not applicable to humans.  A diet of over 4.5:1 is rarely given to 
children and when it is prescribed, it is usually only limited to a few months due to 
possible adverse effects (39). 
 
Karin Borges and her team at Texas Tech University Health Sciences Center 
came a little closer to designing a controlled diet in her most recent study, 
Anticonvulsant profile of a balanced ketogenic diet in acute mouse seizure 
models, Samala, et al., (2008) (76).  Diets in this study included ketogenic diets 
at a 4:1 (TD.06233) and 6:1 (TD.07797) ratio.  Borges took a novel approach in 
diet design by matching vitamins, minerals, and antioxidants across all groups 
relative to their caloric densities.  Yet, with the controls used here, protein and 
 
 33
fiber were not matched among groups.  Interestingly, her results were diverse 
from other findings using similar methods (76).  Four different mouse model 
techniques were used (6-Hz, and 3 different chemicals), and ketogenic diet 
efficacy was only seen in the 6-Hz model at a 6:1 fat to non-fat ratio, not in the 
4:1 ratio (76).  Although the researchers in this study did not draw conclusions in 
this regard, it is interesting to note that previous studies without standardized 
amounts of vitamins, minerals, and antioxidants among groups had different 
findings from this novel approach in diet design.   
 
As scientists are fast at work to uncover the mechanisms that bring about the 
success of the ketogenic diet, examining experimental design is the key to 
insuring results can be interpreted accurately.  When looking for mechanisms 
facilitated by diet, diet design is of great importance.  In previously mentioned 
study designs, several nutrients are not consistent across groups.  One that has 
potential importance is the macronutrient, protein.  In studying the ketogenic diet, 
much focus is given to adding fat and limiting carbohydrate.  Little attention is 
given to maintaining adequate protein.  Yet, in the clinical administration of the 
diet, much attention is given to this vital nutrient for tissue maintenance and 
growth (in children).  In fact, younger children and infants are sometimes 
restricted to a lower ketogenic diet ratio of 3:1 due to higher protein needs per 
kilogram (39).  Thus, clinicians determine the need to provide adequate protein 
more important than maintaining the gold standard ratio of 4:1 (4g fat to 1g non-
fat).  Further, protein can effect overall well being, including brain function.  In 
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fact, Feria-Velasco, et. al., recently reported that low tryptophan and protein 
levels during development can result in increase seizure susceptibility in adult 
rats (77).   Low protein intakes have also been linked to glutamatergic activity in 
the brain of young albino rats resulting in damage to the brain (78).  
 
In low carbohydrate ketogenic diets, including fiber can be challenging.  Fiber is 
an important nutrient in the human diet and high intake has been linked to 
increased health benefits (79).  Dietary fiber can also affect nutrient absorption, 
such fat (80).  Fiber can also adversely affect glucose levels, decreasing 
carbohydrate absorption rates (81).  In studying ketogenic diets, tight control of 
any element that could affect blood glucose is critical.    In manipulating diets and 
evaluating changes brought by this manipulation, dietary fiber needs to remain 
the same to aid in accurately interpreting results.  Vitamins and minerals play an 
important role in maintaining human and animal health.  Lack of nutrients such as 
B-vitamins have been shown to adversely affect learning in growing brains (82).  
Vitamins and minerals play an active role in many metabolic pathways (83).  
Limiting them could hinder pathways, or alter efficacy of the pathways.  These 
nutrients need to be maintained at constant amounts when designing 
experimental diets as to eliminate confounding factors.  Thus, for experiments to 
have a clinical application, experimental designs need to be applicable to 











This animal study was fully conducted in accordance with the NIH Guide for the 
Care and Use of Laboratory Animals.  The Institutional Animal Care and Use 
Committee (IACUC) at the University of Tennessee, Knoxville, TN, approved 
protocols for both breeding animals for this study as well as the protocol used to 
examine the effect ketogenic and calorie restricted diets in epileptic mice.  All 
investigators, laboratory personnel, and volunteers in contact with these animals 
were provided training, passed the examination for  Working With the UT 
Knoxville IACUC course (ResearchTraining.org), and either provided a waiver or 
enrolled into the University of Tennessees occupational health program.   
 
Six breeding pairs of inbred EL/Suz (EL) were donated by Dr. Thomas Seyfried 
from his animal laboratory in the Department of Biology at Boston College 
(Boston, MA).  They were approximately 6 weeks old when they arrived at the 
laboratory located at 1215 W. Cumberland Avenue, Knoxville, TN, Room 319. 
These EL mice were born on 5-21-06 and 5-22-06.  The mice traveled in a 
cardboard animal box containing a wet gel used to keep them cool.  The animals 
were separated by sex and clearly earmarked for identification.  Cage cards from 
BC accompanied the mice, providing information needed for separating the mice 
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into sibling x sibling breeding pairs.  Animals and animal chows were handled 
utilizing sanitary procedures including clean work areas and fully gloved hands. 
 
Eight female and 4 male inbred C57BL/6J mice (B6) approximately 6 weeks old 
were obtained from Jackson Laboratory (Bar Harbor, ME).  These mice arrived in 
a container similar to the El/Suz mice, separated by sex.  Upon arrival, these 
mice were group housed as described above by sex until ready for breeding. 
 
Housing/general care 
Upon arrival, all mice were group housed in plastic shoebox cages with wire bar 
lids and lined with pelleted paper or beta chip bedding (both, Harlan-Teklad, 
Indianapolis, IN) to absorb urine and to provide a means for the animals to 
burrow.  The mice were given ad libitum access to water and AIN-93G purified 
pelleted chow (Dyets, Inc., Bethlehem, PA).  The animals were separated by sex 
and breed and a maximum of 5 adult mice were housed per cage.  All cages 
were clearly marked with an index card listing the mouse strain, the IACUC 
protocol number, the principal investigators (PI) name, PIs University of 
Tennessee telephone number, PIs home telephone number, graduate students 
name, graduate students mobile telephone number, source of the mice, date of 
birth of the mice, and mouse number (when applicable).  Cages were placed on 
a portable stainless steel rack of shelves maintained in a 3-foot by 6-foot 
negative pressure cubicle within the animal laboratory facility, which was labeled 
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Cubicle 8.  The animal laboratory was equipped with a clean/dirty airflow system 
to decrease likelihood of cross contamination between animals housed within the 
facility.  Temperature was maintained at 24 degrees Celsius and relative humidity 
was maintained between 45-75% by an onsite dehumidifier.  The facility was 
maintained on a timer controlled alternating 12:12 hour light-dark cycle.  The 
interruptions of this light-dark cycle was necessary for monitoring during the 
course of EL breeding, when the mice were checked periodically throughout the 
dark, 12 hour night cycle.  During these times, the cubicle light was turned on for 
less than 15 minutes for checking and tending to any newborn pups. All mice 
were allowed ad libitum access to food prior to study randomization.  All EL and 
B6 breeders were fed AIN-93G purified pelleted chow (Dyets, Inc., Bethlehem, 
PA) prior to randomization.  Chow pellets were placed on the floor of the plastic 
shoebox cages of nursing pups beginning at approximately 14 days old until they 
were weaned.  All mice, prior and after randomization, were allowed ad libitum 
access to water provided by a water bottle with sipper tubes placed on each cage 
lid.  Cages were changed weekly on Wednesday mornings at the end of seizure 
testing, unless contraindicated due to breeding and birth of pups.  
 
Due to the stimulation induced seizure susceptibility of the EL mouse strain, 
minimal disturbance was merited.  Therefore, only the PIs laboratory assistants 
and this graduate student were allowed to handle the mice or disturb the cages in 
Cubicle 8.  The only exception included the changing of water bottles by the 
animal laboratory staff if the bottles were less than ½ full.  These bottles were 
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checked daily.  A sign was placed on the door of Cubicle 8 that reminded 
walkers-by that the mice were stress sensitive animals and should not be 
disturbed.  
 
Female HSD:ICR mice were maintained in Cubicle 8 as sentinel mice for periodic 
testing.  During cage changing, a pinch of dirty bedding from each of the mouse 
cages in Cubicle 8 was placed into a clean cage.  The sentinel mice were then 
transferred to this cage to purposefully spread any microbial contaminant that 
may be found in our mice.   These sentinel mice underwent periodic serology 
tests, scotch tape tests and fecal exams to test for contamination.  The results of 
the sentinel mice testing were unremarkable in Cubicle 8 during the time period 
of the experiments describe herein. 
 
Breeding 
The goal in developing the EL/Suz (EL) colony was to breed and grow 20 female 
EL mice that would prove seizure susceptible (see seizure testing below) to 
qualify for the current study.  As described in the above literature review, EL 
colonies can be challenging to grow due to the poor maternal care for pups by 
the EL dams.  Cross-fostering techniques were utilized to optimize success of 
breeding 20 female EL mice to supply the animals needed for the study.   
Black-6 (B) female dams have previously in this animal facility proven suitable to 




To initiate breeding, female B6 mice were placed in clean cages, 2 per cage, and 
then one B6 sibling or cousin male was placed in the occupied females cage for 
group breeding.  Males remained in the cage until female mice displayed 
abdominal distension at which point the female mice were then housed singly.  
Pregnant female mice were provided nestlets (Fisher Scientific, Atlanta, GA) 
made of non-ingestible pulped virgin cotton fiber to aid in nest preparation.   B6 
litters were typically delivered approximately 21 days after the males were placed 
into the females cage.  Upon delivery, mice were left undisturbed (no cage 
changing) for at least 3 days, unless fostering procedures were merited.  The 
timing of breeding the B6 mice was determined based on expected pairing of EL 
mice. At least one B6 female began the breeding cycle 3 days prior to an EL 
mouse pairing in an attempt to have delivery of the B6 pups 1-3 days prior to 
deliver of EL pups.  Our preference was to breed two B6 females prior to each 
EL pairing, as to maximize the potential of having an available foster dam with 
each EL litter. 
 
Female EL mice were single housed in a clean cage prior to breeding.  A sibling 
male EL mouse was placed into the female cage for breeding.  Mice were 
allowed ad libitum access to purified chow and water during the breeding cycle.  
When female EL mice displayed abdominal distension, the male EL mouse was 
removed and the female was given a nestlet for building her nest.  A green 
sticker dot was placed on the cage card to indicate that a pregnant mouse 
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resided there.  Laboratory assistants began checking on the mice every 4-6 
hours, throughout the day and night, on day 19 of breeding and every day 
thereafter until the litter had been dropped. 
 
As expected, the EL dams did not exhibit strong maternal skills.  Typically 
newborn EL pups were found scattered about the cage and cold to the touch.  If 
rescue of these pups was not timely, the pups were already deceased and/or 
partially consumed by the dam. 
 
Cross Fostering 
Upon discovery of a surviving EL litter, pups were cross-fostered to a nursing B6 
dam.  Dr. Gary Truett, University of Tennessee Assistant Professor in the 
Department of Nutrition, provided training on euthanasia of neonate mice by 
decapitation.  Neonate mice do not respond well to CO2 inhalation (84) as is 
standard in euthanasia in older pups and adult mice, therefore quick decapitation 
facilitates a quick and humane means of euthanasia to neonates.  When a 
surviving EL litter was found, a B6 nursing dam was selected to become a foster 
dam to the EL litter.  These B6 litters were typically 1-5 days old when cross-
fostering occurred.  The B6 litter was completely removed from the B6 dams 
nest, while leaving the nest intact.  During this time, her shoebox cage was 
returned to Cubicle 8 with the doors closed to reduce her awareness of 
euthanasia of the pups.  The pups were taken away from Cubicle 8 and quickly 
decapitated with surgical scissors.  The carcasses were disposed of in the 
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carcass freezer in the animal laboratory from which they would later be taken for 
incineration.  After the changing of gloves and removal of any blood products in 
the area, the EL litter to be cross-fostered was gathered into gloved hands.  The 
pups were held for approximately 2 minutes or until they were warmed to the 
point of continuous movement (cold pups have very little movement).  Pups that 
did not move after several minutes of warming were considered expired and their 
carcasses were removed from the litter and disposed of.  When the new EL litter 
was warmed, it was placed gently into the B6 foster dams nest.  Often the B6 
foster dam would scatter the new foster EL litter across the cage and then re-
gather them back into her nest.  The B6 dams used in this breeding experience 
proved to be good foster dams if fostering occurred anywhere between 1 and 5 
days after delivery of her own pups.  Thus, acceptance of the EL litters by the B6 
foster dam was typically good.   
 
Weaning/Ear Marking 
EL mice were nursed and remained with the B6 foster dam until they were 
weaned at 4-5 weeks of age.  At weaning, litter mates were housed by sex and 
ear marked for identification.  At this early age, differentiating between the 
genders can be difficult.  Therefore, occasionally EL litters remained together for 
an additional 1-2 weeks until the genders could be determined at which time they 
were separated.  The ear marking technique used was ear punching, which 
places one or more small notches or holes in the ears at various locations as 
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defined previously by Dickie 1975; Ingalis 1980; Stark and Ostrow 1991.  The 
ear-punching instrument (BTY Co., Bay City, MI) used was washed with soapy 
water and then sanitized with quaternary ammonia before and between uses on 
each mouse.  This procedure requires no anesthesia, as nerve endings are few 
in the ear lobes (pain is therefore minimal).  Offspring of EL breeders were 
numbered beginning with one (1) and numbered to fifty-five (55), without regard 
to litter affiliation or sex. 
 
Experimental Design     
The EL/Suz (EL) mouse model is a well-established epileptic mouse model.  
These animals were descendants of mice received from J. Suzuki at Tokyo (69). 
 
 
Figure 4  EL/Suz mouse bred at the University of Tennessee, Department of Nutrition 




Due to poor nursing and pup retrieval previously observed in females of the EL 
strain, the offspring of these breeding pairs were cross fostered shortly after birth 
to nursing C57BL/6J mice (B6) dams who along with their same B6 male mates 
were purchased from Jackson Laboratories (Bar Harbor, ME).  These B6 foster 
dams continued to nurse and care for these EL pups until they were weaned 
between 4-5 weeks of age.  Upon weaning, the EL pups were group housed by 
sex in plastic shoebox cages with wire rack lids and standard bedding and kept 
on a 12-hour light/dark cycle.  The mice were fed a semi-purified AIN93G 
pelleted rodent chow and were provided water ad libitum.  Dietary intake was 
measured and recorded for the duration of the study.  Weekly seizure testing 
began at weaning (+/- 3 days) and the mice were kept to minimal disturbance (no 
handling) with the exception of weekly seizure testing.  Shortly after the seizure  
testing, the mice were weighed and placed into clean cages.  This was the only 
disturbance they experienced other than passers-by and occasional water bottle 
changes.   
 
This weekly seizure testing, as described under the Seizure Testing section 
below, occurred on Wednesdays between 7:30am-11:00am.  Body weights were 
obtained each week after the seizure testing was complete and the mice were 
placed into clean cages.  At 15-29 weeks of age when seizure consistency had 
been confirmed by a consecutive 2 week seizure score of 4 or 5 according to 
established scoring techniques, female mice were weighed, randomized into one 
of four diet treatment groups (control, control-calorie-restricted, ketogenic, 
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ketogenic-calorie-restricted), and housed in individual cages.  Twenty female 
mice were used in the study and were placed into randomized groups based on 
the date they met study criteria and mouse ear mark number given at weaning.  
Most male mice were euthanized or maintained for breeding.  Male mice were 
also randomized (n=3) for potential inclusion in the event that the colony was 
unable to produce the 20 females required.  The animals were housed at the 
University of Tennessee Nutrition Department animal facility located on the third 
floor of the Jessie Harris Building on the main campus.     
 
Qualifications for Study and Mice Used 
Female EL/Suz (EL) mice that were at least 100 days old and were seizure 
susceptible during the 2 previous seizure testing sessions were included in this 
study.  Mice were considered seizure susceptible if they had a level 4 or 5 
seizure during a seizure testing session (see seizure testing).  Male EL mice 
were excluded from this study due to reports of premature death caused by 
urinary retention.  Mice under 100 days old were excluded due to rapid growth 
during that time in development.  Mice that did not have a level 4 or 5 seizure 
(see seizure testing) during the prior seizure testing session or in the session 





Due to the challenges of breeding an El colony (see Breeding above), not all 
mice in the study were ready to be randomized at the same time; therefore they 
were staggered in placing them in the study.  Once mice were at least 100 days 
old and had experienced seizures for 2 consecutive weeks during seizure testing, 
they were randomized and placed into the study.  When multiple mice became 
ready for the study, their identification numbers were numerically lined up.  
Treatment groups were lined up in this order:  Control (C), control calorie 
restricted (CCR), ketogenic diet (KD), and ketogenic diet calorie-restrict (KDCR).   
At the first randomization, 7 mice were placed into the study.  Mice to be 
randomized were lined up by number and 2 at a time (in numeric order) were 
placed in groups.  The group selection began with control and proceeded with 
control-calorie restricted, ketogenic, and then ketogenic-calorie restricted.  Thus, 
EL2 and EL3 were place in C, EL7 and EL9 were placed in CR, EL10 and EL14 
were place in KD and EL16 was place in KDCR.  Subsequent groups that were 
randomized at later dates were placed in a like manner. 
 
Seizure testing 
Dr. Thomas Seyfried, Professor in the Department of Biology at Boston College 
(BC) provided a short video clip of an EL/Suz (EL) mouse experiencing a seizure 
along with a description for each grade in their established grading scale.  
During a visit to Boston College, this graduate student and the PI were 
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welcomed into Dr. Seyfrieds laboratory and were trained to conduct seizure 
testing on EL mice.  With permission, a video recorder was used to tape this 
training session for future reference as well as for the purpose of sharing the 
session with the collaborating pediatric neurologist, Dr. Christopher A. Miller of 
Child Neurology Services in Knoxville, TN.   
  
Seizure testing and susceptibility scoring was conducted as previously 
established in this model by Todorova et. al., and summarized in figure 6 (85).  
Seizures were precipitated by repetitive handling and simulation of stress 
associated with cage changing.  The testing session was made of 2 trials, 
separated by a 30 minute resting period.  Each trial consisted of 2 testing 
phases.  During the first phase, the mouse was held by the tail for 30 seconds (s) 
10-15 cm above the bedding in its home cage.  The mouse was then placed in a 
clean cage for 2 min.  The mouse was held again (second phase) for 15 s prior to 
being returned to the home cage.  This concluded the first trial.  A second trial 
was conducted after 30 min had elapsed.  Mice developing an epileptic seizure 
during holding were placed immediately in one cage or the other, depending on 
the phase of testing.  Mice experiencing a level 4-5 seizure during the 30 s 
testing phase as defined by Todorova et. al., (85) was not retested for the 15 s 
phase.  Regardless of seizure activity during the 1st trial, the mice were 
undisturbed during the 30 min resting period and then retested for the second 
trial.  Mice were tested weekly during the duration of the study. Seizure 





Mouse is held approx 10-15cm above home cage for 30 seconds 
Mouse is placed into a clean cage for 2 minutes 
Mouse is held again for 15 seconds before being returned to home cage 
Mouse is left undisturbed in home cage for 30 minutes 
Trial 2 
Mouse is held approx 10-15cm above home cage for 30 seconds 
Mouse is placed into a clean cage for 2 minutes 
Mouse is held again before being returned to home cage 
Seizure testing complete 
Mouse is weighed and then placed in a clean cage with fresh bedding 
 
Adapted from EL seizure testing protocol established by Todorova, et al, 1999. 
 
observing mouse response during the testing procedures.  Mice were considered 
seizure susceptible if they experience a generalized seizure during seizure 
testing (score of 4 or 5).  Generalized seizures in the mice involve loss of 
postural equilibrium and consciousness, together with excessive salivation, head, 
limb, and chewing/swallowing automatisms.  Mice limited to vocalization and 
twitching without progression to generalized seizure were not considered seizure  
susceptible for the purpose of this study. Thus, only seizures affecting the entire  
brain were considered in our study, eliminating partial seizures.  All testing 
activity was video recorded for verification.  A summary of severity numbers used 
in the scoring is below.  Dr. Christopher A. Miller, MD reviewed the seizure 
protocol established by BC on the video clip from Boston College as well as the 
video footage taken on the visit to Boston College.  Dr. Miller further visited our  




animal laboratory to verify that the grading of seizures was consistent with the 
grading system established by Todorova et.al (85). 
 
At weaning (4-5 weeks old), EL pups began weekly seizure testing on 
Wednesday mornings between the hours of 0730 and 1100 in the common area 
of the University of Tennessee, Department of Nutrition animal laboratory.  Food 
was removed 2 hours prior to seizure testing.  Food in the cages of the mice that 
were eating ad libitum was gathered from the wire bar lid and placed in an 
aluminum bowl that was marked with the number of the mouse.  The aluminum 
bowl was then placed back down on the wire bar lid.  Thus, the bowl provided a 
barrier for the mice and the food was not accessible to the mice.  The petri dish 
was removed from the cages of mice eating the high fat paste chow.  The 
portable stainless steel rack of shelves on which the mouse cages set was rolled 
from Cubicle 8 to the common animal laboratory workspace.  All counter tops 
used during the seizure testing and other activities were cleaned with quaternary 
ammonia.  Group housed mice were separated by groups of two into cages.  
Earmarks were read and the cages labeled so that mice were identified and 
seizure data could be maintained for individual mice.  To facilitate reading of an 
ear mark, the mouse was gently lifted by the tail and placed on a fisted hand, 
with freedom to walk around the fisted hand (mouse was not constrained other 
than holding of the tail).  While the mouse explored the fisted hand, the 
laboratory assistant could easily view the ear mark and identify the mouse.  Each 
mouse was handled in the same way even if the housing arrangements where 
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such that the mice did not need to be separated, thus each mouse received the 
same low level stimulation consistently before the seizure testing. 
 
The seizure testing station was a table in the middle of the common area in the 
animal laboratory facility.  The laboratory assistants stood beside the table and a 
stainless steel portable shelf was placed behind them as a temporary shelf to 
hold the wire bar lids of the cages of the mice being tested.  All mice were 
seizure tested at the same location in the animal laboratory each week.  The 2 
laboratory assistants worked side-by-side, each responsible for testing a 
maximum of 2 mice at a time (total of 4 mice were typically tested at a time).  An 
additional laboratory assistant was responsible for recording seizure data in a 
notebook and monitoring the timer during the seizure testing.  The timer used 
was a Fisherbrand traceable count down timer (Fisher Scientific, Atlanta, GA) 
with triple line LCD with accuracy to 0.01%.  This graduate student was in charge 
of grading the seizures of the mice and recording video of the session.  This 
graduate student was uniquely qualified to grade the seizures in the mice due to 
the above-mentioned training at Boston College as well as the verification of 
grading obtained from Dr. Christopher Miller. 
 
Seizure severity was measured on the scale of 1 to 5, with 1-3 signifying 
characteristics of a partial seizure and 4-5 signifying characteristics of a 
generalized seizure. See table 1 for a summary of the seizure grading.  A grade 
1 seizure was characterized by squeaking; grade 2 included immobility, blinking 
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and mild facial clonic (rhythmic) activity.  A grade 3 was given if the mouse 
displayed a catatonic tail.  A grade 4 seizure was characterized by forelimb  
rhythmic movements.  A grade 5 was given to any mouse that experienced a 
generalized tonic convulsion involving a lost of posture and full body jerking.   
 
 
For this study, a mouse considered having a generalized seizure was considered 
to be seizure susceptible.  Further, a mouse scoring less than 4 would be 
considered non-susceptible to seizures for that testing session.  Mice achieving a 
generalized seizure (grad 4 or 5) typically began with some of the lower scoring 
characteristics such as squeaking, immobility, twitching and catatonic erect tail 
and then progressed to severe forelimb clonus and generalized convulsion as 
evidenced by loss of postural equilibrium, excessive salivation and severe 
jerking.  
Mice experiencing a level 4 or 5 grade seizure during the 30 second phase of the 
seizure testing were not re-tested in 15 second phase of that same trial.  They 
Table 1  Seizure Severity Scores 
 
Seizure Severity Scores 
Score Characteristics 
1 Squeaking 
2 Immobility, blinking, mild facial clonus 
3 Catatonic posture with erect tail 
4 Forelimb clonus 
5 Generalized tonic convulsion 
 
Adapted from EL seizure testing protocol established by Todorova, et al, 1999 
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were, however, retested in Trial 2, regardless of whether or not the mouse had a 
seizure in the first trial.  This graduate student determined whether or not to 
retest a seizure during the same trial if the mouse had a level 3 seizure.  If the 
mouse appeared still and slow to respond after the 2-minute resting time was 
complete, it was not retested in the 15-second phase.  If the mouse recovered 
quickly from the seizure and was exploring the cage, the mouse would be 
retested during the 15-second phase.  
 
After the seizure testing was complete, the mice were individually weighed on a 
Denver Instrument P-6001 gram scale with precision to 0.1 gram.  An empty 
shoebox cage was placed onto the scale and the scale was tared.  The mouse 
was then placed into the shoebox and the weight was recorded into a notebook 
and maintained on a MS-Excel spreadsheet.  The mouse was then placed into 
their clean cage and returned to the stainless steel shelf. 
 
Before randomization, mouse intake was measured by weighing chow amounts 
each Wednesday morning after the seizure testing was complete.  An aluminum 
cup was place on a Mettler Toledo PG802-S scale with a precision to 0.01 gram 
and the scale was tared to zero. The chow for each cage had been gathered 
from the wire bar lid 2 hours before seizure testing began and placed in an 
aluminum cup that was temporarily stored on top of each cage.  Each cup of food 
was taken to the Mettler scale and weighed by pouring the chow in the tared 
aluminum cup.  This amount was recorded each week into a notebook and 
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maintained on a MS-Excel spreadsheet.  Mice that were randomized into the 
control group were allowed to eat ad libitum; therefore their chow was measured 
in this same manner. 
Blood Collection 
All blood collection occurred via submandibular vein after seizure testing on 
Wednesday mornings, with the exception of the final collection with occurred at 
sacrifice on Saturday mornings. This collection occurred between 1 and 2 hours 
after the seizure testing was complete, to assure blood glucose levels had 
normalized in the event that the mice had experienced seizure activity during the 
testing.  The final blood collection occurred just seconds before decapitation 
which occurred on Saturday mornings.  Therefore, no seizure testing had 
occurred the day that the final blood was taken.   
 
Blood was collected by utilizing the submandibular vein bleeding method.  The 
submandibular vein drains from the brain as well as the cheek pouch, thus giving 
a rich supply of blood.  This vessel is accessed by piercing the vein with a sharp 
object such as a lancet, needle or scalpel.  Pain is minimized with this procedure.  
This graduate student was trained to use the technique by Dr. William Hill, 
Clinical Assistant Professor from the University of Tennessee Office of Lab 
Animal Care.  Golden Rod animal lancets (Medipoint International, Inc., Mineola, 
NY) were used to access this blood vessel.  This lancet was specifically designed 
for this technique of blood collection.  During the collection, mice were held 
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securely and the lancet was used to make a quick, perpendicular puncture to the 
submandibular vein.  The blood was collected into a BD Microtainer plasma 
separator tube (Fisher Scientific, Inc., Atlanta, GA) and quickly placed on ice.  
Pressure was then applied to the cheek of the mouse with a Fisherbrand 2x2 
sterile woven gauze pad (Fisher Scientific, Inc., Atlanta, GA). Quantity of blood 
collected was limited to 200 µl, consistent with the University of Tennessee 
IACUC recommendations limiting the amount of blood taken from an animal to 
the equivalent of 1% of body weight.  As a visual guide for collecting blood, a 
sample tube was prepared with 200µl of water as an upper limit quantity of blood 
to collect at one setting.  This quantity was selected as all mice in the study 
exceeded 20g, thus 200µl served as a safe, conservative blood quantity with 
slight room for error. 
   
Extracting Plasma 
Whole blood was centrifuged in a Sorvall Biofuge Fresco micro-centrifuge 
(Thermofisher Scientific, Asheville, NC) at 6,000 x g for 10 minutes to obtain 
plasma.  The plasma was collected by a Rainin pipet and placed in micro-
centrifuge tubes (Dot Scientific, Flint, MI) and was quickly placed on ice.  The 
tubes were marked with the date and mouse number and the aliquots were 
stored at  80 degrees Celsius until time for analysis.  The plasma samples were 
stored less than six months from the time they entered the freezer until they were 





Plasma samples were thawed from the deep freeze to room temperature.  The 
glucose reagent was prepared and 50ml of sterile deoionized water was loaded 
into a cylinder to make up the solution.  Cuvets were set up for standards and 
samples to include duplicates of each.  Nine hundred µl of glucose reagent was 
added to each cuvet, including standards.  Standards were prepared with the 
following glucose concentrations:  0 mg/dl (water blank), 25 mg/dl, 50 mg/dl, 100 
mg/dl, and 200 mg/dl.  Six µl of standard was added to the standard cuvets.  
Samples were diluted using 4 µl of deionized water and 2 µl of plasma sample to 
each cuvet (including duplicates).  All samples were mixed using a vortex for 
several seconds.  The samples and standards were allowed to incubate at room 
temperature for 10 to 15 minutes.  Samples and standards were then analyzed 
using a Genesys 5 Spectrophotometer.  Data produced by the 
spectrophotometer was then converted using a MS-excel spreadsheet.  The 2 
blank standards were recorded and then the standard dilutions and sample 
readings were recorded.  Then the readings produced by the spectrophotometer 
for the blanks were subtracted from the readings from the standards to give an 
adjusted reading.  This same adjustment was made for the samples (for both 
blanks).  Using the adjusted standards numbers, a slope, a y-intercept and the 
square of the Pearson product correlation coefficient were calculated.  For each 
sample, the two converted numbers (sample minus blank) were averaged 
together and that average was used to calculate a raw glucose score.  The 
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formula used for this calculation is as follows:  (average sample number minus y-
intercept)/slope.  This raw glucose score was then multiplied by a dilution factor 
of 3 to yield the final glucose number that is read as mg/dl. 
 
Beta-Hydroxybutyrate 
Beta-hydroxybutyrate (BHB) was measured as a marker of ketosis.   BHB was 
measured using the Stanbio StatSite® Analyzer (Stanbio, Boerne, TX) 
reflectance meter using the Stanbio β-Hydroxybutyrate LiquiColor® assay kit 
(Stanbio, Boerne, TX).   A single dilution was used to expand the readable range 
to up to 22mM.  Before testing the samples, a calibration was performed using 2 
lot-specific Ketosite® check cards that have been laboratory tested to yield an 
accuracy correlation of y = 0.986x + 0.04,with y = Ketosite® (n=114).  Once both 
check cards gave the reading of CHECK PASS, plasma samples were run.   
The frozen plasma samples were prepared by bringing them to room 
temperature while sitting on the bench top for several minutes.  KetoSite® 
Diluent (Stanbio, Boerne, TX) was used to dilute the sample in order to increase 
the range for the BHB readings.  The KetoSite® Diluent was stored in the freezer 
at  20 degrees Celsius and then after opening was stored in the refrigerator at 4 
degrees Celsius for one month.   The KetoSite® Diluent was allowed to rise to 
room temperature before using.  The samples were processed by making a 1/6 
dilution by placing 5 µl of plasma sample and 25 µl of KetoSite® Diluent into 
clean micro-centrifuge tubes, and then gently vortexing the tube to ensure the 
solution was adequately mixed.    The KetoSite® test cards were stored at room 
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temperature and kept there during testing.  The sample testing began with 
locking a test card into the KetoSite® analyzer.  The screen would display 
Checking until the test card was cleared for use at which time the display would 
ask for the sample.  Twenty-two µl of plasma was delivered by a pipette to the 
reagent pad in the middle of the test card and the door was closed immediately.  
Each sample testing took 1-2 minutes to process before the raw results would 
then be displayed.  The raw scores were recorded in a laboratory manual and 
then placed in a MS-Excel spreadsheet and converted to the final reading by 
accounting for the dilution factor as well as the trace quantity of BHB found in the 
KetoSite® Diluent.  The formula used is as follows: raw data x 6  0.01 = mMol/L 
of sample.   
 
Sacrifice/Tissue collection 
The EL mice were sacrificed by decapitation after 4.5  5.5 weeks on study.  
Whole brains, hearts, kidneys, livers, and fat were obtained for possible analysis 
at a later date.  The common area in the animal lab was divided into 3 stations 
for the sacrifice.  All three stations were thoroughly cleaned with quaternary 
ammonia.  The first station was designated as the blood collection and 
decapitation station.  Mice were taken out of the housing cubby one mouse cage 
at a time to minimize stress of remaining animals.  Once the mouses cage was 
placed at the first station, the mouse was picked up by the tail was then securely 
held.  The ear mark was quickly read to verify the identity of the mouse.  The 
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mouse number was then spoken aloud for all laboratory assistants to verify that 
the materials used for tissue storage were ready for this particular mouse, all 
marked with this particular mouses number and treatment group.  A blood 
sample was taken from the submandibular vein as described in the Blood 
Collection section.  Immediately after the blood sample was taken, the mouse 
was placed in a Decapicone disposable mouse restrainer (Braintree Scientific, 
Braintree, MA) to securely hold the mouse during the decapitation.  The mouse 
was quickly placed in the mouse restrainer and then placed in a small animal 
guillotine and the blade was quickly pulled down to allow for the mouse head to 
be completed separated from the mouse body.  The mouse head was taken to a 
second station for brain extraction.  All surgical instruments used during the 
tissue extraction were soaked in either RNA Later (Fisher Scientific, Atlanta, GA) 
or another RNase inhibitor as to better preserve the tissue in the event that RNA 
analysis is conducted in the future.  The brain was quickly extracted from the 
skull using stainless steel scissors and spatulas.  The brain tissue was then 
weighed and placed in aluminum foil and flash frozen in liquid nitrogen.  
Typically, brains were placed into the liquid nitrogen in less than one minute from 
the time of sacrifice. The mouse body was taken to the third work station in which 
the mouse was opened and the liver was quickly perfused with a sterile 0.9% 
sodium chloride solution until the liver had a visually apparent change in color 
from a dark red to a pale pink which indicates a significant amount of blood had 
been perfused out of the liver.  The liver, heart, kidney and fat pad were each 
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removed, weighed, and flash frozen into liquid nitrogen.  All surgical instruments 
were cleaned with soapy water and rinsed with clear water after each sacrifice. 
 
The sterile sodium chloride solution was made by adding 9 grams of sodium 
chloride to 1 liter of distilled water.  The solution and container was then 
autoclaved for 30 minutes.  After cooling the solution was placed in the 





Upon collection, tissue was quickly placed in aluminum foil and flash frozen by 
submerging into liquid nitrogen.  Tissue was then sealed into plastic bags, 
separated by tissue (heart, kidney, etc.) and group (C, CCR, KD, or KDCR).   
Tissue bags were placed in a cardboard box and marked with PIs name and 




Statistical analysis was conducted using SPSS software (originally named for 
Statistical Package for the Social Sciences) on the following data sets:  weekly 
seizure scores, mouse body weights, beta-hydroxybutyrate, and plasma glucose.  
A general linear univariate analysis of variance was used to test the in-between 
subject effects and a multivariate analysis of variance to measure more than one 
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data point per subject.  Pearson correlations were used to test variable 
influences on different factors.  Independent variable t-tests were used to analyze 
variables and their relationship to seizures.  To find differences between groups, 
a Least Significant Difference (LSD) post hoc test was utilized.  The LSD analysis 
is equivalent to multiple t tests between all pairs of groups and commonly used 
for comparison.  
 
Seizure Scoring 
Weekly seizure scores were analyzed using a chi-square test with the weekly 
seizure scores as the dependant variables, the treatment groups (including the 
control group) as the fixed factor and the change in weight in the 4th week as the 
covariate.  A linear regression with repeated measures was run on the seizure 
data with the weekly seizure scores as the within-subjects variable and the 
between-subjects factor was separated (using 0 or 1) by whether or not the 
mouse was given a ketogenic chow or not (calorie level was not considered with 
this test).  Change in body weight as of the 4th week was used as a covariate in 
this test.  This same linear regression with repeated measures test was ran to 
determine wither or not a calorie restriction effect was present (with no 
consideration of ketogenic or not). 
 
The effects change in body weight by week 4 had on seizures were tested using 
a general univariate analysis of variance.  The standard deviation among the 
data points was calculated using MS-Excel and then the mice were categorized 
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the mice were categorized into groups:  lost weight group (lost more than one 
standard deviation), no weight change group (within one standard deviation), and 
gained weight group (gained more than one standard deviation). A univariate 
analysis of variance was run with the weight categories as fixed factors and the 
seizure scoring results of week 4 of treatment as the dependent variable.  The 
goal was to examine whether or not these categorical divisions could predict 
likelihood of seizure control. 
 
Mouse Body Weights 
A univariate analysis of variance with the group categories as the fixed variables 
was run and the change in weight on the 4th week on study was used as the 
dependent variable.  A LSD post hoc analysis was also performed to better 
determine which groups differed from one another. 
 
Beta-hydroxybutyrate 
A univariate analysis was run to analyze plasma ketone levels.  The group 
categories were used as the fixed variables and the plasma levels of beta-
hydroxybutyrate levels were used as the dependant variable.  This test was run 
with and without the addition of baseline weight used as a covariate.  A LSD post 
hoc was used in this data analysis when the covariate was not used.  This test 




A univariate analysis was run to analyze plasma glucose levels.  The group 
categories were used as the fixed variables and the plasma levels of glucose 
levels at week 4 of treatment were used as the dependant variable.  This test 
was run with and without the addition of baseline weight used as a covariate.  A 
LSD pos hoc was used in this data analysis when the covariate was not used.  
This test helps to better determine where differences lay among the groups.  
These same tests were ran with baseline glucose levels to evaluate whether or 
not levels at treatment week 4 were approaching significance or continuing with 
homogeneity among groups. 
  
Experimental diets 
Composition of Diet 
In order to adequately control for diet composition and caloric intake effects, diets 
were designed to provide consistent amounts of protein, fiber and micronutrients 
across all groups.  This design is especially important as deficiencies of these 
nutrients have the potential to exert independent effects.  Furthermore, our desire 
was to mimic ketogenic diets used in clinical practice.  Typical ketogenic diets 
designed for humans provide Dietary Reference Intake levels (RDAs or AIs) of 
these nutrients (via food and supplements) to prevent deficiencies.  This 
standardization of nutrients was accomplished in the calorie restricted groups by 
formulating purified diets composed of a higher concentration in protein, fiber and 
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micronutrients per gram, thus requiring less chow to provide the same protein, 
fiber and micronutrient content as the normocaloric groups.  In this study, the 
fiber source, cellulose, was not calculated in the total carbohydrate amounts. 
 
All diets in this study were designed in cooperation with Melissa Hansen-Petrik, 
PhD, RD, LDN, of the University of Tennessee Department of Nutrition, 
Knoxville,TN, and Barbara Mickelson, PhD, of Harlan-Teklad, Indianapolis, IN.  
The control diet consisted of a standard semi-purified pelleted rodent chow and 
was fed to the control group ad libitum.  This control diet delivered 3.8 kcal/g of 
energy, 90g protein/kg, 696g carbohydrate/kg, 70g fat/kg, 48g fiber/kg.  The 
control calorie restricted diet consisted of a modified semi-purified pelleted rodent 
chow that delivered 3.8 kcal/g of energy, 121g protein/kg, 619g carbohydrate/kg, 
94g fat/kg, and 64g fiber/kg.  This pelleted chow was pre-weighed and fed to the 
mice daily.  Both of the ketogenic diets were formed into a paste and consisted of 
a modified TD96355 (Harlan-Teklad, Madison, WI), which was based on the 4:1 
(4g fat: 1g protein + carbohydrate) ratio of the classical KD.  The ketogenic diet 
delivered 6.7 kcal/g of energy, 158g protein/kg, 17g carbohydrate/kg, 662g fat/kg, 
and 86g fiber/kg.  The calorie-restricted ketogenic diet delivered 6.1 kcal/g, 197g 
protein/kg, 21g carbohydrate/kg, 585g fat/kg, and 105g fiber/kg.  The percent for 
each nutrient is listed in table 2.  The ratio of fat to non-fat grams for each group 
is as follows: 0.09:1 for the control group; 0.13:1 for the control calorie restricted 
group; 3.77:1 for the ketogenic diet group; and 2.69:1 for the ketogenic calorie 




Each of these ketogenic diets were pre-weighed and given to the mice daily.  The 
experimental ketogenic diets were designed to match total caloric intake, protein 
intake, and micronutrient intake of the control group, so only fat and carbohydrate 
intake were different.  Calorie-restricted mice (control calorie restricted and 
ketogenic calorie restricted groups) consumed diets modified and weighed to 
provide equivalent amounts of protein, fiber, and micronutrients, but with 
carbohydrate and fat content reduced to achieve 75% of the calorie level 
consumed by unrestricted control group.  Chow amounts were determined by 
average energy intake of all mice included in the first set to be randomized.  
Following randomization, experimental diets were fed daily for a period of 4.5-5.5 
weeks.   Dietary intake for the ad libitum fed control group was measured and 
recorded weekly. 
 
Calculation of Diet Amounts 
Before the first set of EL/Suz (EL) mice were randomized, their weekly intake 
was measured and recorded.  These data were used to estimate an average 
daily intake for the mice of 16.34 kcal per day.  This average was used as a 
baseline caloric intake for mice in all groups.  The ketogenic diet group received 
virtually the same calorie amount with 2.4g of ketogenic diet chow providing 
16.08 kcal per day.  The two calorie restricted groups received 75% of this 














Protein 0 38571 0 3866 0 3799 0 3930
Carbohydra 2 99194 1 9816 0 0414 0 0043
Cellulose 0 2064 0 2058 0 2074 0 2093
Fat (g/meal) 0 301 0 2992 1 5894 1 1699
Vit/min mix 0 1763 0 1749 0 1735 0 1761
Calories per 16 34 12 16 16 08 12 20
specially designed pelleted chow which provided 12.16 kcal per day.  The 
ketogenic calorie restricted group received 2.0 grams of the high fat chow 




The researchers were first exposed to the EL mouse model at Boston College 












Dietary Composition: Kcals/g: Control 3.8 kcals/g; Control-CR 3.8 kcals/g KD 6.7 kcals/g;; 
KD-CR 6.1 kcals/g 
 




 C CCR KD KDCR 








Protein 89.7 9.5 120.8 12.7 158.3 9.5 196.5 12.8 
Carbohydrate 695.8 73.8 619.25 65.2 17.25 1 2.15 1.4 
Cellulose 48 11.45 64.32 15.23 86.4 11.7 104.64 15.35 
Fat 70 16.7 93.5 22.1 662.23 89.5 584.93 85.8 
Vit/min mix 41 - 54.66 - 72.28 - 88.07 - 
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Boston, MA by Dr. Thomas Seyfried.  Dr. Seyfried and his graduate student, 
John Mantis, in the Department of Biology at 514 Higgins Hall, Chestnut Hill, 
provided training on seizure testing, breeding suggestions, and handling 
procedures, and suggested methods of feeding a high fat chow (which has a 
pasty consistency) to this mouse model.  The technique used at Boston College 
included a glass petri dish, trimmed to a side height of approximately 1cm.  This 
petri dish was filled with the high fat paste chow and then placed face down on 
the wire rack and then a heavy water bottle was placed on top of the dish so that 
the dish would stay flush against the wire rack lid, thus making the chow 
available for the mice in the cage as they could access the diet through the wires 
of the lid.  This feeding design became the starting point for designing a new, 
more efficient technique.  It was determined that the BC feeding method had 
some limitations such as the inability of the mice to get the chow from behind the 
wires of the wire bar lids.  Chow was observed remaining on the outside of the 
cages where the dish had been as well as remaining in the dish, assuming the 
mouse/mice was/were unable to access it through the wire bars. 
 
In designing a revised method to feed the mice in the ketogenic groups a feeding 
dish that could be suspended in the mouse cage, with no wire or any other object 
obstructing the mouse access to the chow was used in the current study.  A 
polystyrene 60 x 15mm petri dish with snug fitting lid (Fisher Scientific, Atlanta, 
GA) was used as the feeding bowl.  Round magnets were glued to the back of 




            
a.       b.          c. 
weighed on an Ohaus Scott II gram scale (Carlton Scales, Powell, TN) and 
placed in the center of the petri dish.  The lid was placed on the petri dish, thus 
providing an efficient storage method.  When the petri dish was placed on the 
wire rack lid of the cage for feeding, the lid was taken off the petri dish and then 
placed with the magnet facing down, on top of the wire rack lid.  The petri dish 
itself was then placed, magnet up, on the inside of the cage, with the magnets of 
the dish matched with the magnets of the petri dish lid on the outside of the wire 
bar lid.  This utilized an attraction among the magnets that secured the dish in 
place, allowing the mouse easy and complete access to the food.  See figure 7 
below for an overview of this procedure. 
The pelleted chow used for the CCR group needed no special feeding device, as 
it could be placed into the floor of the shoebox cage.  The pellets were weighed 
on the Ohaus Scout II gram scale and pieces of the pellet were chipped off with a 
clean knife to decrease the weight to the desired amount.  Precision for this scale 
 
Figure 6  Magnetic feeding dish:  Feeding method for high fat chow paste  
a.  High fat chow is placed in the center of the petri dish to facilitate easy storage.  b.  Dish 
is opened and placed on the wire bar lid.  c.  Magnets hold feeding dishes in place, 
allowing for easy access for animals. 
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was to 0.1g.  The pellets were then stored in polystyrene tubes until given to 
each mouse. 
 
Polystyrene tubes and feeding petri dishes were labeled with a non-toxic 
permanent marker to identify them by mouse number and the experimental group 
of which they were a part (Example:  #10, KD).  Both the feeding tubes and the 
feeding petri dishes were reused after they were washed in soapy water and air-
dried. 
 
The experimental diets were stored in a freezer at -20 degrees Celsius in bulk 
containers clearly labeled with the expiration date issued by the manufacturer of 
the different chows.  These containers were kept in the bench laboratory located 
at 1215 W Cumberland Ave, Room 342, Knoxville, TN.  Individual daily servings 
were weighed out 3 to 7 days prior to delivery to the mouse.  All chow was 
weighed on an Ohaus Scott II gram scale (Pine Brook, NJ) that has a precision to 
0.1g.  The scale was calibrated after arriving at the laboratory and before being 
used to weigh the chow.  Before each weighing session, the laboratory bench 
area was cleaned with diluted Fisherbrand Versa-Clean Liquid Concentrate 
(Fisher Scientific, Atlanta, GA). Ketogenic diets were weighed directly into the 
feeding dishes.  The control calorie-reduced pellets were weighed in a pre-tared 




The feeding petri dishes for each mouse on a high fat chow were then stored in a 
plastic sealed bag, each mouse having its own bag.  For example, mouse #10 
may have 7 feeding petri dishes in one plastic bag, thus having 7 days worth of 
chow meals ready.  These plastic bags were marked with the mouse number and 
treatment group and were then placed on an aluminum baking pan for easy 
storage.  The tubes filled with the pelleted chow for the control-calorie restricted 
group were also placed in a plastic bag and on the aluminum pan, marked with 
the mouse number and group.  These aluminum baking pans were then 
transferred to the food cooler in the animal laboratory and stored on a shelf 
inside the cooler.  This cooler was maintained at 4 degrees Celsius. 
 
Timing of Feeding 
Mice were fed between 1600 and 1830 nightly.  All laboratory assistants were 
trained extensively before they took on the responsibility of feeding the mice on 
study.  The aluminum pans with the pre-weighed chow were taken out of the 
animal food cooler and placed on a stainless steel table in close vicinity to 
Cubicle 8.  Then, one at a time, each cage was removed from the cubicle and 
placed on a nearby stainless steel table.  The wire bar lid was removed and the 
new food was placed.  The prior days petri dishes for the ketogenic fed mice 
were removed before placing the dish with the fresh chow.  Each cage on study 
had this same procedure.  The control fed mice did not need to be fed daily due 
to the fact that they were fed ad libitum and their wire bar lids were filled with 
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chow.  Yet, to control for this low level of stimulation that occurred during the 
these feeding procedures, the cages of the mice in the control group were 
handled in the same manner.  A cage that housed a mouse in the control group 
was removed from Cubicle 8 and the lid taken off and then replaced, thus 
simulating the stimulation that the other mice were exposed to during the feeding 
process.  The dirty feeding petri dishes and tubes were placed into a designated 
container in the dirty section of the animal laboratory, so they could be later 
washed and reused.  These empty containers were hand washed in soap and 
water and air dried every 3-7 days. 
 
To assure mice were fed within the hours of 1600 and 1830, laboratory 
assistants would confirm via telephone by 1730 that the feeding had been 
completed.  If no call was received by that time, attempts were made to call the 
laboratory assistant responsible for the nights feeding to verify the feeding would 
be completed.  If that laboratory assistant was not reached, a backup plan 
assured that feeding was completed before 1830 hours.  This system was set in 
place as a double check to assure that the animals on study were properly fed at 
the same time every night on the study.  Laboratory assistants signed a feeding 
log placed on the door of Cubicle 8.  This log included the time and date the 








Tolerance of Diets 
 
The mice readily accepted and consumed each of the four diets, both control and 
experimental.  Although diet taste and texture were not consistent across groups, 
primarily due to differing macronutrient fat and carbohydrate concentrations, all 
mice consumed the individual diets with typical interest and eagerness.  Other 
than expected weight loss experienced by mice in the calorie restricted groups, 
no adverse effects were observed in the mice while they were on the study.  This 
is consistent with previous observations in this mouse strain when fed a 
macronutrient modified diet (57).  The appearance and activity level of the mice 
were typical across all groups, similar to appearance and activity of the mice prior 
to randomization and the control group during the study.  This observation was 
casual and not analyzed, as this study did not utilize specific tools to measure 
appearance and activity changes among groups. 
 
Influence of Diets on Weight 
 
At baseline, mice had a mean body weight of 23.8g±SEM and no significant 
differences in baseline body weight were detected among groups by univariate 
analysis.  The two calorie-restricted groups lost weight over the course of the 4-
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week study.  At week 4, univariate analyses revealed a significant reduction in 
weight in the control calorie-restricted group (p<0.01) and the ketogenic calorie-
restricted group (p<0.05) from average baseline weights.  Assignment to 
ketogenic diet treatment (KD or KDCR) had no independent effect on weight 
change from baseline (p=0.238).  Figure 6 illustrates the weights as they 
separated during the course of the study.  
 
Influence of Diets on Plasma Beta-hydroxybutyrate Levels 
Pre-randomization data analyses showed no significant differences in beta-
hydroxybutyrate (BHB) levels among the mice.  It was not until the fourth week of 




























Figure 6  Change in weight from baseline for each group, before treatment and each week 




Results demonstrated a significant difference in BHB levels between treatment 
groups with baseline weight as a covariate (p=0.029) at week 4.  The two groups 
fed ketogenic diets showed significantly higher BHB levels compared to the 
control group at the fourth week, as shown in Figure 7.  The control calorie-
restricted group did not significantly differ from any of the other three groups. 
Calculated mean levels for groups at week 4 included 0.23± 0.05 mMol/L for the 
control group (n=5), 0.43±0.05 mMol/L for the control calorie-restricted (CCR) 
group (n=3), 0.71±0.19 mMol/L for the ketogenic diet (KD) group (n=4), and 
0.75±0.19 mMol/L for the ketogenic calorie-restricted (KDCR) group (n=3). 
Difficulties in blood collection resulted in inadequate volume from some mice and 
inability to complete all assays. 
 
Figure 7   Plasma beta-hydroxybutyrate levels at week 4 of treatment in EL/Suz mice.  
Mice on ketogenic diet regimens (KD & KDCR) had significantly higher BHB levels as 
compared to mice in the control group (C) (p=0.024, p=0.033, respectively).  Calorie 
restriction alone (CCR) did not have a significant effect on plasma BHB levels. Values 
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The control calorie-restricted group did not significantly differ from any of the 
other three groups.   
 
 
Influence of Diets on Plasma Glucose Levels 
 
 No statistically significant differences in plasma glucose levels were observed 
among groups at baseline or during the course of the study.  Figure 8 shows 
glucose levels in the control calorie-restricted group approaching significance as 
compared to the control (p=0.064).      
 
The calculated mean levels for groups at week 4 which included 145±15 mg/dl 
for the control group (n=4), 94±8 mg/dl for the control calorie-restricted (CCR) 
   
Figure 8 - Plasma glucose levels at treatment Week 4 in EL/Suz mice.  No significant 
differences in glucose levels were observed among groups, although levels in the control 
calorie-restricted group (CCR) were nearly significantly lower than those of thecontrol 




















group (n=5), 159±11 mg/dl for the ketogenic diet (KD) group (n=4), and 122±23 
mg/dl for the ketogenic calorie-restricted (KDCR) group (n=3).   
 
 
When the data were analyzed for a main effect of calorie-restriction (C and KD 
vs. CCR and KDCR), a significant difference was found (p=0.011) with calorie-
restricted mice having significantly lower glucose (figure 9).  Confirming this 
finding, a Pearsons correlation showed a significant relationship between weight 
change and glucose levels by week 4 (R=0.568, p=0.017, data not shown) 
indicating that mice experiencing weight loss were more likely to have lower 
glucose levels. 
Thus, calorie restriction and weight loss, regardless of diet composition, were 
associated with lower glucose levels.  
 
Figure 9 - Glucose levels at treatment week 4 in calorie restricted mice (CCR and KDCR) 
exhibited significantly lower blood glucose levels as compared to unrestricted mice (C and 
KD) (p=0.011).  Values shown are means +/- SEM. 


















Influence of Diets on Seizure Control 
 
 
No significant differences in seizure control were observed among treatment 
groups in this study, although possible trends are apparent.  Figure 10 
graphically displays a trend towards seizure control for the ketogenic calorie-
restricted group over the other groups, but no significant differences were 
detected.  Eighty percent of mice in that group had no seizures at week four.  In 
the ketogenic and control calorie-restricted groups, 60% of mice were seizure 
free, while 40% of the control group was seizure free by week 4 of treatment. 
 
The ketogenic diet groups (KD and KDCR) experienced a trend toward seizure 
control over the non-ketogenic groups (C and CR) although the differences were 








































Figure 10  Percentage of EL/Suz mice in each treatment group seizure free pre and post 
randomization to diet treatment group.  By week 4, seizure control was 40% in the control 
group (C), 60% in the control calorie-restricted group (CCR), 60% in the ketogenic diet 
group (KD), and 80% in the ketogenic calorie-restricted group (KDCR).  
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comparing the calorie-restricted groups (CCR and KDCR) with the non-calorie 
restricted groups (C and KD). 
 
 
Weight and biochemical changes according to seizure status 
 
 
As trends in seizure status were apparent among groups, but not readily 
detectable likely due to sample size limitations, body weight change, BHB, and 
glucose values were also analyzed by grouping mice according to seizure status 
at week 4 (see table 4) to determine the relationship between these outcome 
variables with seizure status. 
 
Mouse body weight at week 4 was significantly related to seizure control  
 





Body weight change 
baseline to week 4 (g) 
1.58±0.96* -1.27±0.58* 
BHB (mMol/L) 0.31±0.07 0.58±0.11 
Glucose (mg/dl) 150±18 125±10 
Body weight change, BHB, and glucose levels according to seizure status at week 4.  
Values shown are means ± SEM. Values designated * are significantly different at 




(p=0.006).  Body weight change from baseline to week 4 was also significantly 
different in mice that experienced a seizure at week 4 compared to mice that did 
not (p=0.015).  Mice that lost weight by week 4 were more likely to be seizure 
free, independent of treatment group. 
          .   
Seizure free mice had higher BHB levels than did mice with seizures at week 4, 
although this did not reach statistical significance (p=0.051). No relationship 
































CONCLUSIONS AND DISCUSSION 
 
It has been clearly established that the ketogenic diet is effective in controlling 
seizures (25, 46, 47) .  Although the treatment was stumbled upon many years 
ago, even today, how the diet works remains unclear.  Researchers from all over 
the world (40) seek to find those answers and many theories have been 
proposed.   
 
When investigating efficacy of a dietary treatment in an animal model, 
experimental diet design is of utmost importance.  In this case, experimental 
ketogenic diets designed to test mechanisms must be tightly controlled and 
reflect the composition of the clinical diet, as efficacy has been shown time and 
time again (25, 46, 47).  Prior animal research has largely ignored this mantra 
(57)  and this limits applicability of findings from those studies. 
 
Previous studies of ketogenic diet efficacy in animal models of epilepsy have not 
controlled for protein, fiber, and micronutrients (57).  Rather, diet manipulation 
has focused on carbohydrate and fat differences and energy restriction without 
regard for other dietary components or utilization of a proper control diet.  When 
displacing macronutrients or when restricting calories, typical study designs 
simply change amounts of fat and carbohydrate or simply limit the amount of 
food provided (57).  When restricting portions, all nutrients are affected; in 
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addition to reducing total energy intake, animals also consume a protein, fiber, 
and micronutrient deficient diet.  Energy restriction implemented in this way can 
influence metabolism and alter gene expression.  For example, low protein intake 
has been shown to be affect brain function (77).  Therefore, it is unclear whether 
findings from such studies are due solely to energy restriction or if results are 
also influenced by protein deficiency, altered fiber intake, or micronutrient 
deficiency.  Fiber can impact absorption, which directly affects metabolism (79, 
81).  Vitamins and minerals are utilized in many metabolic pathways (83), 
therefore availability of these nutrients in experimental diets needs to be 
standardized when seeking mechanisms respondent to diet manipulation. 
 
Therefore, the aim of the present study was to test the efficacy of a novel highly- 
controlled experimental diet design as a new gold standard for ketogenic diet 
manipulation to search for mechanisms in animal models of epilepsy. This study 
is innovative, as nutrient composition was strictly controlled across groups for 
protein, fiber, and macronutrient intake while manipulating only the energy intake 
and content of carbohydrate and fat.  
 
The results from this study suggest that ketosis indicated by elevated BHB levels 
and energy restriction indicated by weight loss correspond to lower seizure 
susceptibility in an experimental model of naturally occurring epilepsy. This is 
consistent with previous findings (57) but is even more telling because dietary 
components, excepting carbohydrate and fat, were consistent across groups and 
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the overall diets reflected the ketogenic diet in clinical practice rather than an 
extreme not applicable to humans. While there was an apparent trend, a 
statistically significant difference in seizure control was not observed among 
individual experimental diet groups. It is likely that a non-extreme diet 
intervention, as used here, requires a larger sample size in order to detect 
differences among groups. Thus, a larger sample size could have potentially 
better delineated these trends and more clearly defined the effects. 
 
Importantly, the observation that KD fed mice with or without energy restriction 
had higher BHB levels and mice without seizures at week 4 had a nearly 
significantly higher serum BHB level is consistent with prior reports that ketogenic 
diet treatment reduces seizure susceptibility in EL mice (57).  It is possible that 
BHB plays a direct role in seizure control as has been previously observed (56).  
It is also possible that BHB is only serving as a marker of metabolic changes 
consistent with ketogenic diet treatment as has been suggested by others (86).  
The observed connection between weight loss and seizure susceptibility is 
likewise consistent with the profound effect of energy restriction observed 
previously by Mantis et al. (57).  They found that a reduced caloric intake, 
regardless of the source of the kcalories, was more anti-epileptic than a 
ketogenic diet (57).  It is possible that the implementation of energy restriction in 
these studies concluded efficacy due to the more severe nature of the energy 
restriction itself or the deficiency of protein or other micronutrients.  Mantis and 
his group induced a weight loss of 20-23% of baseline body weight.  Regardless 
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of caloric sources, this could be construed as truly starving the mouse as 
opposed to mimicking the metabolism of starvation, such as with a ketogenic 
diet.  This type of starvation is not clinically applicable.  The small sample size of 
the present study limited the ability to detect a potential direct effect of energy 
restriction on seizure control. For example, one mouse in the calorie-restricted 
ketogenic diet group gained weight. As mice in each group were provided an 
identical quantity of food regardless of starting weight it is possible that some 
energy-restricted mice received quantities greater than their physiological 
requirement.  It is likewise possible that some non-calorie restricted mice 
received less than their physiological requirement. Therefore, possibly the energy 
restriction of some mice could have caused unexpected seizure control.  In all, a 
larger sample size could have strengthened the ability to detect a direct effect of 
energy restriction. Consequently, it is helpful to examine the effect of energy 
restriction by using weight change as a proxy. When seizure susceptibility was 
analyzed, weight did prove to be a strong predictor of seizure control, with 
improved seizure control in mice with lower body weights and/or weight loss from 
baseline. Certainly, weight loss could be considered a proxy for energy restriction 
whereas weight gain could be considered a proxy for energy excess. 
Interestingly, a ketogenic effect on weight was not observed.   
In this study there appeared to be an intermediate, albeit non-significant, effect 
on BHB with energy restriction alone, which might be expected.  Interestingly, 
Mantis et al. found BHB levels increased in the control calorie-restricted group as 
well as both ketogenic diet groups (57).  This inconsistency from the current 
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findings is likely due to the extreme calorie restriction Mantis and his team placed 
on the calorie-restricted groups more clearly eliciting ketosis. 
 
Calorie-restricted mice (fed either ketogenic or control diets) did have 
significantly lower glucose levels than the mice that were fed ketogenic diets 
(p=0.011).  Mantis observed a correlation between lower blood glucose levels 
and seizure control in EL mice (57) and postulated that adequate glucose levels 
are necessary to precipitate a seizure.  Currently, researchers at Massachusetts 
General Hospital are exploring the connection between reducing serum glucose 
and seizure control clinically by placing children on a low glycemic index 
treatment (LGIT) in order to maintain lower glucose levels.  This diet is reported 
to be easier on families to administer and less restrictive.  Some preliminary data 
on this deviation of the classic ketogenic diet appear promising (44), yet 
clinicians studying this diet admit it is doubtful that the LGIT will replace or be as 
effective as the classic ketogenic diet (Dr. EA Thiele, Massachusetts General, 
live presentation, Boston, MA, 2006). This coincides with one of the current 
hypotheses that ketogenic diets could be effective due to limited glucose 
availability for precipitation of a seizure (54, 55).   
 
Uncovering the mechanism(s) of action for the ketogenic diet is a much-needed 
effort, which could ultimately be used to refine the diet treatment, thereby making 
it more effective.  Also, understanding more about the diet could expand its use 
and improve more lives affected by epilepsy.  If the diet could be simplified, it 
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would likely be more aggressively used for intractable epilepsy or possibly be 
used earlier in treatment to avoid undesirable side effects of anti-epileptic drugs.  
Further, uncovering the mechanism(s) of action could give great insights into the 
disorder of epilepsy. Experiments utilizing laboratory animals can lead to better 
understanding the way in which ketogenic diets alter substrate utilization in the 
brain could give insight into how this diet can control seizures.  Processes and 
tissue utilization can be explored and then applied to humans. Understanding 
what effectively treats a disorder, could allow better understanding of the disorder 
itself.   Yet, researchers have not stopped at epilepsy, but are now questioning 
whether ketogenic diets have potential roles in other disease states.  
Researchers have reported some positive preliminary results in treating 
Parkinsons disease (87, 88) , amyotrophic lateral sclerosis (ALS) (89), traumatic 
brain injury (87), stroke (87), Alzheimers (87), obesity with high cholesterol (90), 
prostate cancer (91, 92) and brain cancer (93-95) with ketogenic diets.  
 
Perhaps Macfadden, the fanatical fitness guru of the early 1900s, wasnt as 
crazy as researchers may have presumed when he promoted his ideas of 
curing all disease states by fasting and exercise (13).  Although it is unlikely that 
all disease states can be treated with a diet that mimics fasting, it does appear as 
though researchers have only scratched the surface of the potential roles 
ketogenic diets may play in healthcare in the future.   Yet, before all the 
metabolic alterations induced by this treatment in the human body can be fully 
understood, researchers must first look at how animal models are influenced by 
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this treatment.  And since this treatment is a therapeutic diet, the design of 
experimental diets to study it must be well controlled if these studies are to give 
meaningful insight into the mechanisms of action. The experimental diet design 
utilized in the present study is the first tightly controlled ketogenic diet design to 
be described and, if adopted by basic scientists in the ketogenic diet research 
community, has the potential to make research results in this area more 
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